Professor Wayne Tilley

Director - Dame Roma Mitchell Cancer Res Lab

Adelaide Medical School

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Professor Wayne Tilley is the Director of the Dame Roma Mitchell Cancer Research Laboratories (DRMCRL), Adelaide Medical School, the University of Adelaide. His research career has spanned some 40 years in Australia, the USA and the UK, and has led to international acclaim as a world expert in the field of nuclear receptors and hormonal carcinogenesis. Professor Tilley’s research has an emphasis on mechanisms of sex hormone signalling and the emergence of resistance to hormonal therapies used in the treatment of breast and prostate cancer. He is internationally recognised for discoveries on steroid hormone receptor action, in particular androgen receptor (AR) structure and function (including cloning the human androgen receptor in the late 1980’s at UT Southwestern Medical School, Dallas TX) and AR function in breast and prostate cancers. He was one of the first to describe perturbations in AR signalling critical to progression of prostate cancer, including evidence for the oncogenic potential of the AR. Most recently, his research has provided evidence that the AR is a tumour suppressor in estrogen receptor (ER)-positive breast cancer and that the progesterone receptor (PR) can inhibit ER action in human breast cancer tissues by a novel reprograming mechanism (Nature 2015; Nature Medicine 2021). This research has led to 4 clinical trials of AR and PR activation in ER-driven disease.

Professor Tilley’s research is unique in leveraging similarities in breast and prostate cancer to forge new insights into disease mechanisms and novel treatment strategies. Research in the DRMCRL uses contemporary genomic techniques and unique patient-derived model (PDEs, PDXs) systems to gain a deeper understanding into how sex hormones and their receptors control tumour behaviour. This information is used to develop new treatment strategies, with a clear view to improving patient outcomes.

Professor Tilley’s research has attracted significant funding from government, non-government and philanthropic sources. He has published over 225 peer-reviewed papers. In 2016 he received the Endocrine Society of Australia Senior Plenary Award and gave the introductory Plenary Lecture at the 2016 International Congress of Endocrinology in Beijing, China. He was Chair of the 2015 Gordon Research Conference on Hormone-Dependent Cancers and a co-chair of the recent Fusion Nuclear Receptor Meeting in Mexico (4-7 May, 2022). Professor Tilley convenes the International PacRim Breast and Prostate Cancer Meeting Series.

My Research
Career
Publications
Grants and Funding
Supervision
Professional Activities
Contact

The Dame Roma Mitchell Cancer Research Laboratories (DRMCRL) have an international reputation for research into sex hormone action in hormone-dependent cancers, with a particular emphasis on breast and prostate cancers.

This world-class cancer research centre brings together expertise spanning more than 30 years in basic and translational prostate and breast cancer research. It is the leading centre in Australia with a multidisciplinary team of scientists, clinicians and patient advocates dedicated to understanding how sex hormones and their receptors control tumour behaviour in both disease contexts. The information is used to understand mechanisms of resistance to existing hormonal therapies for breast and prostate cancer and in developing new strategies for disease treatment and management. Research programs span discovery, drug development and clinical translation.

A major research focus at the DRMCRL is the development of novel androgen receptor (AR) and progesterone receptor (PR) targeted therapies for breast and prostate cancer. In prostate cancer, this involves the generation of drugs to inhibit aberrant forms of the AR that drive the disease and are unresponsive to conventional androgen deprivation therapies. In the case of breast cancer, our research has led to new strategies to activate the AR or PR to inhibit growth of tumours that are driven by the estrogen receptor (ER), as well as interrogation of Selective Androgen Receptor Modulators (SARMs), which have the ability to reprogram oncogenic AR activation in ER negative breast cancer.

Our laboratory has pioneered integration of genomic technologies with unique preclinical models of human breast and prostate cancers, especially patient-derived explant cultures and xenograft models, to better understand disease mechanisms and facilitate translation of breast and prostate cancer research into the clinic.

We publish in high impact journals such as Nature, Nature Genetics, Nature Reviews Cancer, Cancer Research, Clinical Cancer Research and Oncogene. Our research is well supported by funding from nationally and internationally competitive grants. The DRMCRL offers students a wide array of projects that span cutting-edge biomedical research using contemporary pre-clinical models, genome-wide technologies and access to large proteomic/genomic databases.

We are currently actively seeking students interested in bioinformatics to interrogate these databases, with opportunities of cross faculty supervision in fields such as mathematics and machine learning.

Key Research Projects Available for DRMCRL

Project 1 - Transforming endocrine therapy for breast and prostate cancer

Description - Breast and prostate cancers are diseases driven by abnormal sex hormone receptor activity mediated by the estrogen receptor (ER) in breast and the androgen receptor (AR) in prostate cancers. Surgery and radiation therapy for these diseases work well when the tumour is confined within the organ of origin. However, for cancers that have spread out of the breast or prostate, either locally or to other parts of the body, the major treatment strategy is to completely abolish the activity of the offending sex hormone receptor. This treatment strategy is called hormone deprivation therapy and has been employed for the past century. Overwhelming evidence indicates that hormone deprivation therapy has run its course in providing a survival advantage to people with breast or prostate cancer.

Our hypothesis is that reprogramming estrogen or androgen receptors (ER and AR) away from oncogenic activity toward more benign activity will transform endocrine therapy for breast and prostate cancer. In this project we aim to discover optimal strategies to reprogram ER or AR activity in breast and prostate cancer by investigating three complementary approaches to reprogramming ER/AR: 1) Activate other nuclear receptors that directly inhibit ER/AR signalling; 2) Utilize selective ER/AR ligands; and 3) Enhance ER/AR reprogramming with epigenetic drugs. We will then validate optimal reprogramming strategies in patient-derived xenograft “clinical trials” and clinical samples.

Available for: Honours and HDR

Start Date: Semester 1 and 2 2023

Project 2 - Selective activation of androgen receptor to treat estrogen receptor positive breast cancer

Description - Androgens, acting via the androgen receptor (AR), a protein related to the estrogen receptor (ER), are natural inhibitors of estrogen-stimulated breast cancer growth. Although androgens are commonly considered to be male hormones, females produce androgens throughout their life. AR typically is present in the same cells as ER, resulting in estrogen and androgen hormones exerting opposing forces on the growth of ER-positive breast cancers, with estrogen having growth promoting and androgens protective effects.

The goals of this project are: 1) Investigate how stimulation of the androgen receptor (AR) by a synthetic androgen which has been shown to be well tolerated by women, inhibits the growth of estrogen-sensitive breast tumours; and 2) Develop and evaluate proteins identified as being potential biomarkers of response to androgenic therapies.

Available for: Honours and HDR

Start Date: Semester 1 and 2 2023

Project 3 - The clinical significance of sex hormone crosstalk in estrogen receptor positive breast cancer

Description - Breast cancer is mainly a disease in which the sex hormone estrogen stimulates uncontrolled growth via the estrogen receptor (ER). We have recently discovered that other sex hormones, including progesterone and androgen, can redirect the actions of estrogen in breast cancers to halt growth or make a tumour disappear. This project will examine the complex interaction between all three sex hormones to develop new, more effective strategies for treating breast cancer.

In this project, we will investigate the three-way interplay between ER, PR (progesterone receptor) and AR (androgen receptor) in contemporary models of breast cancer including patient derived xenografts and ex-vivo cultured primary tumour tissues. The ultimate goal is to determine clinical scenarios in which PR, AR or both could be optimally therapeutically targeted to treat ER+ breast cancer, particularly disease resistant to current ER targeting drugs.

Available for: Honours and HDR

Start Date: Semester 1 and 2 2023

Project 4 - Pushing AR toward better outcomes in breast and prostate cancers

Description - This project will establish the efficacy of drugs called SARMs (selective androgen receptor modulators) for re-activating the normal, non-oncogenic function of the AR (androgen receptor) in human-derived pre-clinical models and clinical samples of breast and prostate cancers. Currently available SARMs (eg Enobosarm) have excellent safety profiles, and are poised for rapid implementation into clinical trials. Through our collaborations with clinicians that currently run breast cancer and prostate cancer clinical trials, we have access to breast cancer and prostate cancer samples, and also an avenue to prepare them to quickly implement novel treatment strategies that arise from this project.

The aims of this project are: 1) Identify SARMs that reprogram AR from oncogenic to benign genomic loci in breast cancers and prostate cancers; 2) Identify proteins that mediate AR reprogramming in breast and prostate cancers; 3) Pre-clinically test selected SARMs with therapeutic potential; and 4) Determine the clinical scope for SARMs and candidate biomarkers derived during the project.

Available for: Honours and HDR

Start Date: Semester 1 and 2 2023

Project 5 - Targeting CDK9 in triple negative and endocrine-resistant breast cancers

Description - Triple negative breast cancer (TNBC) is the worst form of breast cancer at diagnosis. Better treatments for these cancers is a critical unmet need. TNBC preferentially aﬄicts young women and those with mutations of the BRCA1 gene. Another very aggressive form of breast cancer is estrogen receptor (ER) driven cancer that becomes resistant to ER targeting therapies. Chemotherapy and more recently, CDK4/6 inhibitors are the only approved means of treating these cancers, but survival rates remain low.

This project focuses on these highly aggressive breast cancers that collectively cause the majority of breast cancer-related death. Such cancers have phenomenal rates of growth, in part due to elevated transcriptional activation of oncogenes. In collaboration with a medicinal chemist (Prof Shudong Wang), we are testing new drugs that speciﬁcally target CDK9, a factor that can ramp up the transcriptional activity of RNA polymerase II. The goals of this project are: 1) Demonstrate the eﬃcacy of novel CDK9 inhibitors in a unique suite of patient-derived xenograft models of triple negative and endocrine-resistant breast cancer; 2) Identify cellular mediators of CDK9-targeted therapy in these disease subtypes; and 3) Test our CDK9 inhibitors in prospectively-collected patient derived explant tumours cultured ex vivo and evaluate a biomarker signature of treatment response.

Available for: Honours and HDR

Start Date: Semester 1 and 2 2023

Appointments

Date	Position	Institution name
2014 - ongoing	Visiting Professorship	University of Turku
2012 - 2014	Visiting Scientist, Cancer Research UK	Cambridge University
2006 - ongoing	Co-Director	Adelaide Prostate Cancer Research Centre
2002 - ongoing	Director, Dame Roma Mitchell Cancer Research Laboratories	The University of Adelaide
2001 - 2002	Visiting Fellow, Norris Comprehensive Cancer Center	University of Southern California
1996 - 2001	Director, Flinders Cancer Centre	Flinders University
1992 - 1998	NHMRC Senior Research Fellow	Flinders University
1991 - 1992	NHMRC CJ Martin Fellow	Flinders University
1989 - 1991	Visiting Fellow, Department of Internal Medicine	University of Texas Southwestern Medical Center
1987 - 1989	NHMRC CJ Martin Fellow	University of Texas Southwestern Medical Center
1983 - 1986	NHMRC Senior Research Officer, Department of Surgery	Flinders University

Awards and Achievements

Date	Type	Title	Institution Name	Country	Amount
2016	Award	2016 Senior Plenary Award	Endocrine Society of Australia	Australia	-
2015	Award	Executive Dean’s Awards 2015	The University of Adelaide	Australia	-
2008	Award	Ron Ross Award	4th PacRim Breast and Prostate Cancer Meeting	Canada	-

Education

Date Institution name Country Title

1984 Flinders University of South Australia Australia PhD

1976 University of Adelaide Australia B. Sc (Hons)
Postgraduate Training

Date Title Institution Country

1987 - 1989 NHMRC CJ Martin Fellow University of Texas Southwestern Medical Center at Dallas United States
Research Interests

Cancer Cell Biology Cancer Therapy Cancer Biology and Clinical Oncology Innovative Therapeutics

Date	Institution name	Country	Title
1984	Flinders University of South Australia	Australia	PhD
1976	University of Adelaide	Australia	B. Sc (Hons)

Date	Title	Institution	Country
1987 - 1989	NHMRC CJ Martin Fellow	University of Texas Southwestern Medical Center at Dallas	United States

Journals

Year	Citation
2024	Bhuva, D. D., Tan, C. W., Salim, A., Marceaux, C., Pickering, M. A., Chen, J., . . . Davis, M. J. (2024). Library size confounds biology in spatial transcriptomics data. Genome Biology, 25(1), 99-1-99-10. DOI Scopus1 Europe PMC3
2024	Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis. Cancer Research, 84(14), 2313-2332. DOI
2024	Hosseinzadeh, L., Kikhtyak, Z., Laven-Law, G., Pederson, S. M., Puiu, C. G., D'Santos, C. S., . . . Hickey, T. E. (2024). The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer. Genome Biol, 25(1), 44-1-44-28. DOI Scopus3 Europe PMC1
2024	Palmieri, C., Linden, H., Birrell, S. N., Wheelwright, S., Lim, E., Schwartzberg, L. S., . . . Overmoyer, B. (2024). Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. The Lancet Oncology, 25(3), 317-325. DOI Scopus4
2024	Rahman, R., Rahaman, M. H., Hanson, A. R., Choo, N., Xie, J., Townley, S. L., . . . Selth, L. A. (2024). CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer. British Journal of Cancer, 131(6), 1092-1105. DOI
2024	De Ieso, M. L., Aldoghachi, A. F., Tilley, W. D., & Dwyer, A. R. (2024). Are androgen receptor agonists a treatment option in bladder cancer?. The Journal of steroid biochemistry and molecular biology, 106623. DOI
2023	Huang, X., Reye, G., Momot, K. I., Blick, T., Lloyd, T., Tilley, W. D., . . . Hugo, H. J. (2023). Portable NMR for the investigation of models of mammographic density <i>ex vivo</i>: Androgens antagonise the promotional effect of oestrogen. BIOMEDICAL SPECTROSCOPY AND IMAGING, 10(3-4), 77-97. DOI
2023	Raths, F., Karimzadeh, M., Ing, N., Martinez, A., Yang, Y., Qu, Y., . . . Knott, S. R. V. (2023). The molecular consequences of androgen activity in the human breast. Cell Genomics, 3(3), 100272-1-100272-29. DOI Scopus7 Europe PMC6
2023	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Tables S2-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. DOI
2023	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Table S1 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. DOI
2023	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Figures S1-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. DOI
2023	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Figures S1-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. DOI
2023	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Data from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. DOI
2023	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Tables S2-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. DOI
2023	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Table S1 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. DOI
2023	Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2023). Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. DOI
2023	Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2023). Supplementary Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. DOI
2023	Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2023). Supplementary Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. DOI
2023	Horsfall, A. J., Chav, T., Pederick, J. L., Kikhtyak, Z., Vandborg, B. C., Kowalczyk, W., . . . Bruning, J. B. (2023). Designing Fluorescent Nuclear Permeable Peptidomimetics to Target Proliferating Cell Nuclear Antigen. Journal of Medicinal Chemistry, 66(15), 10354-10363. DOI
2023	Prekovic, S., Chalkiadakis, T., Roest, M., Roden, D., Lutz, C., Schuurman, K., . . . Zwart, W. (2023). Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity. EMBO Molecular Medicine, 15(12), 17 pages. DOI Scopus4 WoS1 Europe PMC3
2023	Wang, A., Shen, J., Rodriguez, A. A., Saunders, E. J., Chen, F., Janivara, R., . . . Weinstein, S. (2023). Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nature Genetics, 55(12), 2065-2074. DOI Scopus14 WoS1 Europe PMC17
2023	Mustafa, E. H., Laven-Law, G., Kikhtyak, Z., Nguyen, V., Ali, S., Pace, A. A., . . . Hickey, T. E. (2023). Selective inhibition of CDK9 in triple negative breast cancer. Oncogene, 43(3), 202-215. DOI Scopus2
2022	A, M., Owen, K. L., Townley, S., Zanker, D., Rollin, S. P. G., Hanson, A. R., . . . Selth, L. A. (2022). Potent Stimulation of the Androgen Receptor Instigates a Viral Mimicry Response in Prostate Cancer. Cancer research communications, 2(7), 706-724. DOI Scopus7 WoS1 Europe PMC4
2021	Kenigsberg, A. P., Tilley, W. D., & Raj, G. V. (2021). Jean Wilson and His Legacy, 50 Years and Counting. Urology, 153, 1-5. DOI
2021	Huang, X., Reye, G., Momot, K. I., Blick, T., Lloyd, T., Tilley, W. D., . . . Hugo, H. J. (2021). Corrigendum: Heparanase Promotes Syndecan-1 Expression to Mediate Fibrillar Collagen and Mammographic Density in Human Breast Tissue Cultured ex vivo (Front. Cell Dev. Biol., (2020), 8, 599, 10.3389/fcell.2020.00599). Frontiers in Cell and Developmental Biology, 9, 678589. DOI Scopus1
2021	Choo, N., Ramm, S., Luu, J., Winter, J. M., Selth, L. A., Dwyer, A. R., . . . Simpson, K. J. (2021). High-throughput imaging assay for drug screening of 3D prostate cancer organoids. SLAS Discovery, 26(9), 1107-1124. DOI Scopus36 WoS20 Europe PMC27
2021	Jillson, L. K., Yette, G. A., Laajala, T. D., Tilley, W. D., Costello, J. C., & Cramer, S. D. (2021). Androgen receptor signaling in prostate cancer genomic subtypes. Cancers, 13(13), 3272. DOI Scopus15 WoS11 Europe PMC13
2021	Hickey, T. E., Dwyer, A. R., & Tilley, W. D. (2021). Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer. British Journal of Cancer, 125(12), 1599-1601. DOI Scopus4 WoS3 Europe PMC2
2021	Horsfall, A. J., Vandborg, B., Kikhtyak, Z., Scanlon, D. B., Tilley, W. D., Hickey, T. E., . . . Abell, A. D. (2021). A cell permeable bimane-constrained PCNA-interacting peptide. RSC Chemical Biology, 2(5), 1499-1508. DOI Scopus5 WoS3 Europe PMC2
2021	Davies, A., Nouruzi, S., Ganguli, D., Namekawa, T., Thaper, D., Linder, S., . . . Zoubeidi, A. (2021). An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.. Nature cell biology, 23(9), 33 pages. DOI Scopus75 WoS43 Europe PMC65
2021	Che, M., Chaturvedi, A., Munro, S. A., Pitzen, S. P., Ling, A., Zhang, W., . . . Dehm, S. M. (2021). Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nature Communications, 12(1), 6377-1-6377-15. DOI Scopus12 WoS9 Europe PMC11
2021	Conti, D. V., Darst, B. F., Moss, L. C., Saunders, E. J., Sheng, X., Chou, A., . . . Haiman, C. A. (2021). Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 53(1), 65-75. DOI Scopus248 WoS177 Europe PMC213
2021	Fernandes, R. C., Toubia, J., Townley, S., Hanson, A. R., Dredge, B. K., Pillman, K. A., . . . Selth, L. A. (2021). Post-transcriptional gene regulation by microRNA-194 promotes neuroendocrine transdifferentiation in prostate cancer. Cell Reports, 34(1), 1-17. DOI Scopus30 WoS23 Europe PMC24
2021	Conti, D. V., Darst, B. F., Moss, L. C., Saunders, E. J., Sheng, X., Chou, A., . . . Haiman, C. A. (2021). Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.. Nature genetics, 53(3), 413. DOI Scopus7 WoS1 Europe PMC4
2021	Hickey, T. E., Selth, L. A., Chia, K. M., Laven-Law, G., Milioli, H. H., Roden, D., . . . Tilley, W. D. (2021). The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nature Medicine, 27(2), 310-320. DOI Scopus131 WoS89 Europe PMC96
2021	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S., . . . Swinnen, J. V. (2021). Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition. Cancer Research, 81(19), 4981-4993. DOI Scopus44 WoS26 Europe PMC35
2021	Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2021). ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer. Cancer Research, 81(7), 1704-1718. DOI Scopus47 WoS36 Europe PMC34
2020	Portman, N., Milioli, H. H., Alexandrou, S., Coulson, R., Yong, A., Fernandez, K. J., . . . Lim, E. (2020). MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.. Breast cancer research : BCR, 22(1), 87. DOI Scopus42 WoS29 Europe PMC33
2020	Huang, X., Reye, G., Momot, K. I., Blick, T., Lloyd, T., Tilley, W. D., . . . Hugo, H. J. (2020). Heparanase Promotes Syndecan-1 Expression to Mediate Fibrillar Collagen and Mammographic Density in Human Breast Tissue Cultured ex vivo.. Front Cell Dev Biol, 8, 599. DOI Scopus16 WoS11 Europe PMC10
2020	Hollis, B., Day, F. R., Busch, A. S., Thompson, D. J., Soares, A. L. G., Timmers, P. R. H. J., . . . Butler, L. (2020). Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan. Nature Communications, 11(1), 1536-1-1536-10. DOI Scopus37 Europe PMC23
2020	Tadesse, S., Anshabo, A. T., Portman, N., Lim, E., Tilley, W., Caldon, C. E., & Wang, S. (2020). Targeting CDK2 in cancer: challenges and opportunities for therapy.. Drug discovery today, 25(2), 406-413. DOI Scopus173 WoS108 Europe PMC89
2020	Jankovic-Karasoulos, T., Bianco-Miotto, T., Butler, M. S., Butler, L. M., McNeil, C. M., O'Toole, S. A., . . . Ricciardelli, C. (2020). Elevated levels of tumor apolipoprotein D independently predict poor outcome in breast cancer patients. Histopathology, 76(7), 976-987. DOI Scopus20 WoS11 Europe PMC13
2020	Flach, K. D., Periyasamy, M., Jadhav, A., Dorjsuren, D., Siefert, J. C., Hickey, T. E., . . . Zwart, W. (2020). Endonuclease FEN1 coregulates ERα activity and provides a novel drug interface in tamoxifen resistant breast cancer. Cancer Research, 80(10), 1914-1926. DOI Scopus20 WoS17 Europe PMC10
2019	Moore, N. L., Hanson, A. R., Ebrahimie, E., Hickey, T. E., & Tilley, W. D. (2019). ANTI-proliferative transcriptional effects of medroxyprogesterone acetate in Estrogen receptor positive breast cancer cells are predominantly mediated by ThE progesterone receptor.. Journal of Steroid Biochemistry and Molecular Biology, 199, 105548. DOI Scopus14 WoS7 Europe PMC5
2019	Fernandes, R. C., Hickey, T. E., Tilley, W. D., & Selth, L. A. (2019). Interplay between the androgen receptor signaling axis and microRNAs in prostate cancer. Endocrine-Related Cancer, 26(5), R237-R257. DOI Scopus22 WoS19 Europe PMC15
2019	Chia, K. M., Milioli, H., Portman, N., Laven-Law, G., Coulson, R., Yong, A., . . . Lim, E. (2019). Non-canonical AR activity facilitates endocrine resistance in breast cancer. Endocrine-Related Cancer, 26(2), 251-264. DOI Scopus26 WoS24 Europe PMC24
2019	Schumacher, F. R., Olama, A. A. A., Berndt, S. I., Benlloch, S., Ahmed, M., Saunders, E. J., . . . Rosenstein, B. S. (2019). Correction to: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (Nature Genetics, (2018), 50, 7, (928-936), 10.1038/s41588-018-0142-8). Nature Genetics, 51(2), 363. DOI Scopus6 WoS5 Europe PMC8
2019	Tadesse, S., Caldon, E. C., Tilley, W., & Wang, S. (2019). Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update. Journal of Medicinal Chemistry, 62(9), 4233-4251. DOI Scopus168 WoS138 Europe PMC89
2019	Matejcic, M., Saunders, E. J., Dadaev, T., Brook, M. N., Wang, K., Sheng, X., . . . Ranu, H. (2019). Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1). Nature Communications, 10(1), 5 pages. DOI Scopus1 WoS1 Europe PMC2
2019	Zhang, A. Y., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. G. (2019). An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. International Journal of Cancer, 144(5), 1151-1159. DOI Scopus12 WoS11 Europe PMC7
2019	Tarulli, G., Laven-Law, G., Shehata, M., Walters, K., Denis, I., Rahman, M., . . . Hickey, T. (2019). Androgen receptor signalling promotes a luminal phenotype in mammary epithelial cells. Journal of Mammary Gland Biology and Neoplasia, 24(1), 99-108. DOI Scopus7 WoS4 Europe PMC5
2019	Warren, A., Massie, C., Watt, K., Luko, K., Orafidiya, F., Selth, L., . . . Asim, M. (2019). A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. Oncogene, 38(7), 1136-1150. DOI Scopus18 WoS15 Europe PMC10
2018	Lawrence, M., Obinata, D., Sandhu, S., Selth, L., Wong, S., Porter, L., . . . Frydenberg, M. (2018). Patient-derived models of abiraterone- and enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy. European Urology, 74(5), 562-572. DOI Scopus83 WoS65 Europe PMC59
2018	Centenera, M. M., Hickey, T. E., Jindal, S., Ryan, N. K., Ravindranathan, P., Mohammed, H., . . . Tilley, W. D. (2018). A patient-derived explant (PDE) model of hormone-dependent cancer. Molecular Oncology, 12(9), 1608-1622. DOI Scopus86 WoS65 Europe PMC67
2018	Snell, C., Gough, M., Liu, C., Middleton, K., Pyke, C., Shannon, C., . . . Tilley, W. (2018). Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b. British Journal of Cancer, 119(11), 1316-1325. DOI Scopus8 WoS8 Europe PMC7
2018	Luo, J., Attard, G., Balk, S., Bevan, C., Burnstein, K., Cato, L., . . . Raj, G. (2018). Role of androgen receptor variants in prostate cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 73(5), 715-723. DOI Scopus102 WoS93 Europe PMC70
2018	Ricciardelli, C., Bianco-Miotto, T., Jindal, S., Butler, L., Leung, S., McNeil, C., . . . Tilley, W. (2018). The magnitude of androgen receptor positivity in breast cancer is critical for reliable prediction of disease outcome. Clinical Cancer Research, 24(10), 2328-2341. DOI Scopus63 WoS53 Europe PMC51
2018	Centenera, M., Selth, L., Ebrahimie, E., Butler, L., & Tilley, W. (2018). New opportunities for targeting the androgen receptor in prostate cancer. Cold Spring Harbor Perspectives in Medicine, 10(12), 1-19. DOI Scopus22 WoS18 Europe PMC15
2018	Pillman, K. A., Phillips, C. A., Roslan, S., Toubia, J., Dredge, B. K., Bert, A. G., . . . Gregory, P. A. (2018). miR-200/375 control epithelial plasticity-associated alternative splicing by repressing the RNA-binding protein Quaking. EMBO Journal, 37(13), 20 pages. DOI Scopus77 WoS64 Europe PMC57
2018	Schumacher, F., Al Olama, A., Berndt, S., Benlloch, S., Ahmed, M., Saunders, E., . . . Lu, Y. (2018). Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 50(7), 928-936. DOI Scopus542 WoS443 Europe PMC454
2018	Dadaev, T., Saunders, E., Newcombe, P., Anokian, E., Leongamornlert, D., Brook, M., . . . Sellers, T. (2018). Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 9(1), 19 pages. DOI Scopus76 WoS65 Europe PMC70
2018	Shafi, A., Schiewer, M., de Leeuw, R., Dlygeri, E., McCue, P., Shah, N., . . . Knudsen, K. (2018). Novel patient derived models reveal the impact of the tumor microenvironment on therapeutic response. European Urology Oncology, 1(4), 325-337. DOI Scopus38 WoS34 Europe PMC32
2018	Matejcic, M., Saunders, E. J., Dadaev, T., Brook, M. N., Wang, K., Sheng, X., . . . Butler, L. (2018). Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 9(1), 4616-1-4616-11. DOI Scopus42 WoS34 Europe PMC37
2017	Miao, L., Yang, L., Li, R., Rodrigues, D., Crespo, M., Hsieh, J., . . . Raj, G. (2017). Disrupting androgen receptor signaling induces Snail-mediated epithelial-mesenchymal plasticity in prostate cancer. Cancer Research, 77(11), 3101-3112. DOI Scopus61 WoS43 Europe PMC47
2017	Paltoglou, S., Das, R., Townley, S., Hickey, T., Tarulli, G., Coutinho, I., . . . Selth, L. (2017). Novel androgen receptor coregulator GRHL2 exerts both oncogenic and antimetastatic functions in prostate cancer. Cancer Research, 77(13), 3417-3430. DOI Scopus73 WoS59 Europe PMC65
2017	Nelson, A. W., Groen, A. J., Miller, J. L., Warren, A. Y., Holmes, K. A., Tarulli, G. A., . . . Carroll, J. S. (2017). Corrigendum to “Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity” [Mol. Cell Endocrinol. 440 (2016) 138–150] (S0303720716304853)(10.1016/j.mce.2016.11.016). Molecular and Cellular Endocrinology, 443(C), 175. DOI Scopus3 WoS2
2017	Das, R., Gregory, P. A., Fernandes, R. C., Denis, I., Wang, Q., Townley, S. L., . . . Selth, L. A. (2017). MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2. Cancer Research, 77(4), 1021-1034. DOI Scopus97 WoS88 Europe PMC67
2017	Ponnusamy, S., Coss, C., Thiyagarajan, T., Watts, K., Hwang, D. -J., He, Y., . . . Narayanan, R. (2017). Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer. Cancer Research, 77(22), 6282-6298. DOI Scopus65 WoS54 Europe PMC42
2017	Selth, L., Das, R., Townley, S., Coutinho, I., Hanson, A., Centenera, M., . . . Tilley, W. (2017). A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene, 36(1), 24-34. DOI Scopus90 WoS84 Europe PMC60
2017	Nelson, A., Groen, A., Miller, J., Warren, A., Holmes, K., Tarulli, G., . . . Carroll, J. (2017). Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity. Molecular and Cellular Endocrinology, 440(C), 138-150. DOI Scopus91 WoS86 Europe PMC68
2017	Carroll, J. S., Hickey, T. E., Tarulli, G. A., Williams, M., & Tilley, W. D. (2017). Deciphering the divergent roles of progestogens in breast cancer. Nature Reviews Cancer, 17(1), 54-64. DOI Scopus96 WoS86 Europe PMC64
2016	Tilley, W. D. (2016). Novel twists in hormone-mediated carcinogenesis. Endocrine-Related Cancer, 23(12), E9-E12. DOI
2016	Lim, E., Palmieri, C., & Tilley, W. D. (2016). Renewed interest in the progesterone receptor in breast cancer. British Journal of Cancer, 115(8), 909-911. DOI Scopus31 WoS25 Europe PMC20
2016	Lim, E., Tarulli, G., Portman, N., Hickey, T., Tilley, W., & Palmieri, C. (2016). Pushing estrogen receptor around in breast cancer. Endocrine-Related Cancer, 23(12), T227-T241. DOI Scopus32 WoS32 Europe PMC23
2016	Coutinho, I., Day, T., Tilley, W., & Selth, L. (2016). Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocrine-Related Cancer, 23(12), T179-T197. DOI Scopus133 WoS118 Europe PMC100
2016	Philp, L., Day, T., Butler, M., Laven-Law, G., Jindal, S., Hickey, T., . . . Tilley, W. (2016). Small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA) ablation limits offspring viability and growth in mice. Scientific Reports, 6(1), 28950-1-28950-14. DOI Scopus8 WoS8 Europe PMC7
2016	Singhal, H., Greene, M., Tarulli, G., Zarnke, A., Bourgo, R., Laine, M., . . . Greene, G. (2016). Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Science Advances, 2(6), e1501924. DOI Scopus97 WoS89 Europe PMC83
2016	Hu, D., Selth, L., Tarulli, G., Meech, R., Wijayakumara, D., Chanawong, A., . . . Hickey, T. (2016). Androgen and estrogen receptors in breast cancer coregulate human UDP-glucuronosyltransferases 2B15 and 2B17. Cancer Research, 76(19), 5881-5893. DOI Scopus47 WoS41 Europe PMC33
2016	Carter, S., Centenera, M., Tilley, W., Selth, L., & Butler, L. (2016). IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. BMC Cancer, 16(1), 141-1-141-13. DOI Scopus12 WoS11 Europe PMC7
2016	Carter, S. L., Centenera, M. M., Tilley, W. D., Selth, L. A., & Butler, L. M. (2016). Erratum to: IΚBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.[BMC Cancer. 2016] 16:141. Doi: 10.1186/s12885-016-2188-2.. BMC Cancer, 16(1), 1 page. DOI Europe PMC1
2016	Asim, M., Massie, C., Orafidiya, F., Pértega-Gomes, N., Warren, A., Esmaeili, M., . . . Neal, D. (2016). Choline kinase alpha as an androgen receptor chaperone and prostate cancer therapeutic target. Journal of the National Cancer Institute, 108(5), djv371-1-djv371-13. DOI Scopus40 WoS35 Europe PMC30
2016	Castro, M., De Santiago, I., Campbell, T., Vaughn, C., Hickey, T., Ross, E., . . . Meyer, K. (2016). Regulators of genetic risk of breast cancer identified by integrative network analysis. Nature Genetics, 48(1), 12-21. DOI Scopus137 WoS119 Europe PMC113
2016	Bonilla, C., Lewis, S. J., Martin, R. M., Donovan, J. L., Hamdy, F. C., Neal, D. E., . . . Tilley, W. (2016). Pubertal development and prostate cancer risk: mendelian randomization study in a population-based cohort. BMC Medicine, 14(1), 66. DOI Scopus39 WoS39 Europe PMC32
2015	Al Olama, A. A., Benlloch, S., Antoniou, A. C., Giles, G., Severi, G., Neal, D. E., . . . Mason, M. (2015). Risk analysis of prostate cancer in practical, a multinational consortium, using 25 known prostate cancer susceptibility loci. Cancer Epidemiology Biomarkers and Prevention, 24(7), 1121-1129. DOI Scopus54 WoS48 Europe PMC43
2015	Stegeman, S., Amankwah, E., Klein, K., O Mara, T. A., Kim, D., Lin, H. Y., . . . Luedeke, M. (2015). A large-scale analysis of genetic variants within putative miRNA binding sites in prostate cancer. Cancer Discovery, 5(4), 368-379. DOI Scopus51 WoS51 Europe PMC39
2015	Raj, G. V., Selth, L. A., Day, T. K., & Tilley, W. D. (2015). Evolution of androgen deprivation therapy. Cancer Forum, 39(3), 189-194. WoS1
2015	Chan, S., Selth, L., Li, Y., Nyquist, M., Miao, L., Bradner, J., . . . Dehm, S. (2015). Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Research, 43(12), 5880-5897. DOI Scopus127 WoS121 Europe PMC102
2015	Tarulli, G., Laven-Law, G., Shakya, R., Tilley, W., & Hickey, T. (2015). Hormone-sensing mammary epithelial progenitors: emerging identity and hormonal regulation. Journal of Mammary Gland Biology and Neoplasia, 20(1-2), 75-91. DOI Scopus13 WoS11 Europe PMC10
2015	Hickey, T., Irvine, C., Dvinge, H., Tarulli, G., Hanson, A., Ryan, N., . . . Selth, L. (2015). Expression of androgen receptor splice variants in clinical breast cancers. Oncotarget, 6(42), 44728-44744. DOI Scopus75 WoS60 Europe PMC55
2015	Tuck, A., Robker, R., Norman, R., Tilley, W., & Hickey, T. (2015). Expression and localisation of c-kit and KITL in the adult human ovary. Journal of Ovarian Research, 8(1), 31-1-31-12. DOI Scopus25 WoS21 Europe PMC15
2015	Mohammed, H., Russell, I., Stark, R., Rueda, O., Hickey, T., Tarulli, G., . . . Carroll, J. (2015). Progesterone receptor modulates ERα action in breast cancer. Nature, 523(7560), 313-317. DOI Scopus483 WoS422 Europe PMC357
2015	Centenera, M., Carter, S., Gillis, J., Marrocco-Tallarigo, D., Grose, R., Tilley, W., & Butler, L. (2015). Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. Endocrine-Related Cancer, 22(5), 805-818. DOI Scopus24 WoS23 Europe PMC18
2015	Mohammed, H., Russell, I. A., Stark, R., Rueda, O. M., Hickey, T. E., Tarulli, G. A., . . . Carroll, J. S. (2015). Erratum: Progesterone receptor modulates ERα action in breast cancer (Nature (2015) 523 313-317 DOI:10.1038/nature14583). Nature, 526(7571), 144. DOI Scopus11 WoS14 Europe PMC7
2015	Tuck, A., Mottershead, D., Fernandes, H., Norman, R., Tilley, W., Robker, R., & Hickey, T. (2015). Mouse GDF9 decreases KITL gene expression in human granulosa cells. Endocrine, 48(2), 686-695. DOI Scopus7 WoS4
2014	Selth, L. A., Roberts, M. J., Chow, C. W. K., Marshall, V. R., Doi, S. A. R., Vincent, A. D., . . . Gardiner, R. A. (2014). Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers. Endocrine-Related Cancer, 21(4), L17-L21. DOI Scopus33 WoS30 Europe PMC26
2014	Das, R., Gregory, P., Hollier, B., Tilley, W., & Selth, L. (2014). Epithelial plasticity in prostate cancer: principles and clinical perspectives. Trends in Molecular Medicine, 20(11), 643-651. DOI Scopus21 WoS20 Europe PMC16
2014	Hilton, H., Doan, T., Dinny Graham, J., Oakes, S., Silvestri, A., Santucci, N., . . . Clarke, C. (2014). Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease. Oncotarget, 5(18), 8651-8664. DOI Scopus25 WoS22 Europe PMC19
2014	Tarulli, G. A., Butler, L. M., Tilley, W. D., & Hickey, T. E. (2014). Bringing androgens up a NOTCH in breast cancer. Endocrine-Related Cancer, 21(4), T183-T202. DOI Scopus25 WoS24 Europe PMC19
2014	McNamara, K. M., Moore, N. L., Hickey, T. E., Sasano, H., & Tilley, W. D. (2014). Complexities of androgen receptor signalling in breast cancer. Endocrine-Related Cancer, 21(4), T161-T181. DOI Scopus114 WoS101 Europe PMC76
2014	Doan, T., Eriksson, N., Graham, D., Funder, J., Simpson, E., Kuczek, E., . . . Clarke, C. (2014). Breast cancer prognosis predicted by nuclear receptor-coregulator networks. Molecular Oncology, 8(5), 998-1013. DOI Scopus18 WoS16 Europe PMC11
2014	Akram, O. N., DeGraff, D. J., Sheehan, J. H., Tilley, W. D., Matusik, R. J., Ahn, J. M., & Raj, G. V. (2014). Tailoring peptidomimetics for targeting protein-protein interactions. Molecular Cancer Research, 12(7), 967-978. DOI Scopus42 WoS34 Europe PMC27
2014	Nelson, A. W., Tilley, W. D., Neal, D. E., & Carroll, J. S. (2014). Estrogen receptor beta in prostate cancer: friend or foe?. Endocrine-Related Cancer, 21(4), T219-T234. DOI Scopus86 WoS71 Europe PMC49
2014	Oh, T., Bailey, P., Dray, E., Smith, A., Goode, J., Eriksson, N., . . . Muscat, G. (2014). PRMT2 and RORγ expression are associated with breast cancer survival outcomes. Molecular Endocrinology, 28(7), 1166-1185. DOI Scopus49 WoS40 Europe PMC32
2014	Ochnik, A., Moore, N., Jankovic-Karasoulos, T., Bianco-Miotto, T., Ryan, N., Thomas, M., . . . Hickey, T. (2014). Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo. Menopause, 21(1), 79-88. DOI Scopus17 WoS13 Europe PMC12
2014	Claessens, F., & Tilley, W. (2014). Androgen signalling and steroid receptor crosstalk in endocrine cancers. Endocrine Related Cancer, 21(4), E3-E5. DOI Scopus5 WoS5 Europe PMC5
2014	Hu, D., Hickey, T., Irvine, C., Wijayakumara, D., Lu, L., Tilley, W., . . . MacKenzie, P. (2014). Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues. Hormones and Cancer, 5(2), 61-71. DOI Scopus57 WoS48 Europe PMC44
2014	Robinson, J., Hickey, T., Warren, A., Vowler, S., Carroll, T., Lamb, D., . . . Carroll, J. (2014). Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype. Oncogene, 33(50), 5666-5674. DOI Scopus69 WoS63 Europe PMC57
2013	Comstock, C., Augello, M., Goodwin, J., de Leeuw, R., Schiewer, M., Ostrander, W., . . . Knudsen, K. (2013). Targeting cell cycle and hormone receptor pathways in cancer. Oncogene, 32(48), 5481-5491. DOI Scopus93 WoS79 Europe PMC71
2013	Knower, K., Chand, A., Eriksson, N., Takagi, K., Miki, Y., Sasano, H., . . . Clyne, C. (2013). Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Research and Treatment, 142(1), 211-223. DOI Scopus41 WoS35 Europe PMC27
2013	Philp, L., Butler, M., Hickey, T., Butler, L., Tilley, W., & Day, T. (2013). SGTA: A new player in the molecular co-chaperone game. Hormones and Cancer, 4(6), 343-357. DOI Scopus27 WoS24 Europe PMC24
2013	Lawrence, M., Ormsby, R., Blyth, B., Bezak, E., England, G., Newman, M., . . . Sykes, P. (2013). Lack of high-dose radiation mediated prostate cancer promotion and low-dose radiation adaptive response in the TRAMP mouse model. Radiation Research, 180(4), 376-388. DOI Scopus5 WoS4 Europe PMC3
2013	Trotta, A., Need, E., Selth, L., Chopra, S., Pinnock, C., Leach, D., . . . Buchanan, G. (2013). Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation. International Journal of Cancer, 133(12), 2812-2823. DOI Scopus19 WoS18 Europe PMC18
2013	Lawrence, M., Blyth, B., Ormsby, R., Tilley, W., & Sykes, P. (2013). False-positive TUNEL staining observed in SV40 based transgenic murine prostate cancer models. Transgenic Research, 22(5), 1037-1047. DOI Scopus12 WoS8 Europe PMC7
2013	Centenera, M., Raj, G., Knudsen, K., Tilley, W., & Butler, L. (2013). Ex vivo culture of human prostate tissue and drug development. Nature Reviews, Urology, 10(8), 483-487. DOI Scopus112 WoS103 Europe PMC94
2013	Selth, L., Townley, S., Bert, A., Stricker, P., Sutherland, P., Horvath, L., . . . Tilley, W. (2013). Circulating microRNAs predict biochemical recurrence in prostate cancer patients. British Journal of Cancer, 109(3), 641-650. DOI Scopus113 WoS110 Europe PMC88
2013	Gillis, J., Selth, L., Centenera, M., Townley, S., Sun, S., Plymate, S., . . . Butler, L. (2013). Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget, 4(5), 691-704. DOI Scopus49 WoS45 Europe PMC39
2013	Abankwa, D., Millard, S., Martel, N., Choong, C., Yang, M., Butler, L., . . . Leong, G. (2013). Ski-interacting protein (SKIP) interacts with androgen receptor in the nucleus and modulates androgen-dependent transcription. BMC Biochemistry, 14(10), 1-9. DOI Scopus14 WoS12 Europe PMC13
2013	Butler, M., Yang, X., Ricciardelli, C., Liang, X., Norman, R., Tilley, W., & Hickey, T. (2013). Small glutamine-rich tetratricopeptide repeat-containing protein alpha is present in human ovaries but may not be differentially expressed in relation to polycystic ovary syndrome. Fertility and Sterility, 99(7), 2076-2083. DOI Scopus5 WoS4 Europe PMC4
2013	Ravindranathan, P., Lee, T., Yang, L., Centenera, M., Butler, L., Tilley, W., . . . Raj, G. (2013). Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nature Communications, 4(5), 1923-1-1923-11. DOI Scopus118 WoS111 Europe PMC83
2013	Butler, M., Ricciardelli, C., Tilley, W., & Hickey, T. (2013). Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression. Hormones and Cancer, 4(3), 154-164. DOI Scopus20 WoS16 Europe PMC17
2013	Muscat, G., Eriksson, N., Byth, K., Loi, S., Graham, D., Jindal, S., . . . Clarke, C. (2013). Research resource: Nuclear receptors as transcriptome: Discriminant and prognostic value in breast cancer. Molecular Endocrinology, 27(2), 350-365. DOI Scopus88 WoS82 Europe PMC79
2013	Centenera, M., Fitzpatrick, A., Tilley, W., & Butler, L. (2013). Hsp90: still a viable target in prostate cancer. Biochimica et Biophysica Acta-Reviews on Cancer, 1835(2), 211-218. DOI Scopus44 WoS39 Europe PMC28
2013	Chiam, K., Ryan, N., Ricciardelli, C., Day, T., Buchanan, G., Ochnik, A., . . . Bianco-Miotto, T. (2013). Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers. Prostate, 73(2), 182-193. DOI Scopus15 WoS13 Europe PMC12
2013	Lange, C. A., Hankinson, S. E., & Tilley, W. D. (2013). Updates from the Editors. Hormones and Cancer, 4(3), 121-122. DOI
2012	Robinson, J. L., Brown, G. D., Neal, D. E., Tilley, W. D., & Carroll, J. S. (2012). Androgen receptor driven transcription in a subtype of estrogen receptor negative breast cancer is controlled by FoxA1. Cancer Research, 72(Suppl.8), 1 page. DOI
2012	Need, E., Selth, L., Harris, T., Birrell, S., Tilley, W., & Buchanan, G. (2012). Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor α in luminal breast cancer cells. Molecular Endocrinology, 26(11), 1941-1952. DOI Scopus73 WoS65 Europe PMC60
2012	Trotta, A., Need, E., Butler, L., Selth, L., O'Loughlin, M., Coetzee, G., . . . Buchanan, G. (2012). Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client. Journal of Molecular Endocrinology, 49(2), 57-68. DOI Scopus19 WoS17 Europe PMC17
2012	Hickey, T., Robinson, J., Carroll, J., & Tilley, W. (2012). Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?. Molecular Endocrinology, 26(8), 1252-1267. DOI Scopus236 WoS208 Europe PMC168
2012	Dowhan, D., Harrison, M., Eriksson, N., Bailey, P., Pearen, M., Fuller, P., . . . Muscat, G. (2012). Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes. Endocrine-Related Cancer, 19(4), 509-526. DOI Scopus34 WoS29 Europe PMC26
2012	Moore, N., Buchanan, G., Harris, J., Selth, L., Bianco-Miotto, T., Hanson, A., . . . Tilley, W. (2012). An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocrine-Related Cancer, 19(4), 599-613. DOI Scopus47 WoS44 Europe PMC32
2012	Selth, L., Tilley, W., & Butler, L. (2012). Circulating microRNAs: macro-utility as markers of prostate cancer?. Endocrine-Related Cancer, 19(4), 99-113. DOI Scopus39 WoS34 Europe PMC29
2012	Dean, J., McClendon, A., Hickey, T., Butler, L., Tilley, W., Witkiewicz, A., & Knudsen, E. (2012). Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle, 11(14), 2756-2761. DOI Scopus188 WoS163 Europe PMC143
2012	Centenera, M., Gillis, J., Hanson, A., Jindal, S., Taylor, R., Risbridger, G., . . . Butler, L. (2012). Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clinical Cancer Research, 18(13), 3562-3570. DOI Scopus94 WoS89 Europe PMC73
2012	Moore, N., Hickey, T., Butler, L., & Tilley, W. (2012). Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells. Molecular and Cellular Endocrinology, 357(1-2), 60-70. DOI Scopus39 WoS38 Europe PMC21
2012	Thompson, V., Day, T., Bianco-Miotto, T., Selth, L., Han, G., Thomas, M., . . . Tilley, W. (2012). A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. International Journal of Cancer, 131(3), 662-672. DOI Scopus30 WoS28 Europe PMC23
2012	Selth, L., Townley, S., Gillis, J., Ochnik, A., Murti, K., Macfarlane, R., . . . Butler, L. (2012). Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. International Journal of Cancer, 131(3), 652-661. DOI Scopus162 WoS140 Europe PMC120
2012	Schiewer, M., Goodwin, J., Han, S., Brenner, J., Augello, M., Dean, J., . . . Knudsen, K. (2012). Dual roles of PARP-1 promote cancer growth and progression. Cancer Discovery, 2(12), 1134-1149. DOI Scopus335 WoS299 Europe PMC250
2012	Robinson, J. L. L., MacArthur, S., Ross-Innes, C. S., Tilley, W. D., Neal, D. E., Mills, I. G., & Carroll, J. S. (2012). Erratum: Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1 (The EMBO Journal (2012) 31 (1617) DOI:10.1038/emboj.2012.59). EMBO Journal, 31(6), 1617. DOI Scopus2 WoS3
2011	Robinson, J., MacArthur, S., Ross-Innes, C., Tilley, W., Neal, D., Mills, I., & Carroll, J. (2011). Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO Journal, 30(15), 3019-3027. DOI Scopus237 WoS214 Europe PMC194
2011	Chiam, K., Centenera, M., Butler, L., Tilley, W., & Bianco-Miotto, T. (2011). GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells. PLoS One, 6(9), e25634-1-e25634-11. DOI Scopus46 WoS36 Europe PMC31
2011	Peters, A., Ingman, W., Tilley, W., & Butler, L. (2011). Differential effects of exogenous androgen and an androgen receptor antagonist in the peri- and postpubertal murine mammary gland. Endocrinology, 152(10), 3728-3737. DOI Scopus53 WoS46 Europe PMC38
2011	Buchanan, G., Need, E., Barrett, J., Bianco-Miotto, T., Thompson, V., Butler, L., . . . Coetzee, G. (2011). Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells. Molecular and Cellular Endocrinology, 342(1-2), 20-31. DOI Scopus12 WoS12 Europe PMC12
2011	Atlantis, E., Lange, K., Goldney, R., Martin, S., Haren, M., Taylor, A., . . . Wittert, G. (2011). Specific medical conditions associated with clinically significant depressive symptoms in men. Social Psychiatry and Psychiatric Epidemiology, 46(12), 1303-1312. DOI Scopus27 WoS21 Europe PMC16
2010	Bianco-Miotto, T., Chiam, K., Buchanan, G., Jindal, S., Day, T., Thomas, M., . . . Ricciardelli, C. (2010). Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiology Biomarkers & Prevention, 19(10), 2611-2622. DOI Scopus136 WoS112 Europe PMC84
2010	Hu, D., Gardner-Stephen, D., Severi, G., Gregory, P., Treloar, J., Giles, G., . . . MacKenzie, P. (2010). A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide. Molecular Pharmacology, 78(4), 714-722. DOI Scopus28 WoS26 Europe PMC23
2010	Ricciardelli, C., Bianco-Miotto, T., Jindal, S., Dodd, T., Cohen, P., Marshall, V., . . . Horsfall, D. (2010). Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies. Cancer Epidemiology Biomarkers & Prevention, 19(7), 1755-1765. DOI Scopus11 WoS11 Europe PMC9
2010	Callen, D., Ricciardelli, C., Butler, M., Stapleton, A., Stahl, J., Kench, J., . . . Holm, R. (2010). Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome. Oncology Reports, 23(4), 1045-1052. DOI Scopus12 WoS10 Europe PMC9
2010	Baglietto, L., Severi, G., English, D., Krishnan, K., Hopper, J., McLean, C., . . . Giles, G. (2010). Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiology Biomarkers & Prevention, 19(2), 492-502. DOI Scopus92 WoS83 Europe PMC60
2010	Risbridger, G., Davis, I., Birrell, S., & Tilley, W. (2010). Breast and prostate cancer: more similar than different. Nature Reviews. Cancer, 10(3), 205-212. DOI Scopus200 WoS187 Europe PMC148
2010	Need, E., O'Loughlin, P., Armstrong, D., Haren, M., Martin, S., Tilley, W., . . . Buchanan, G. (2010). Serum testosterone bioassay evaluation in a large male cohort. Clinical Endocrinology, 72(1), 87-98. DOI Scopus5 WoS4 Europe PMC1
2010	Ochnik, A. M., Jankovic-Karasoulos, T., Cops, E. J., Birrell, S. N., Butler, L. M., Jindall, S., . . . Hickey, T. E. (2010). Medroxyprogesterone acetate impedes 5 alpha-dihydrotesterone induced androgen receptor signaling in normal and malignant human breast epithelial cells. Cancer Research, 70(Suppl 8), 4 pages. DOI
2010	Murti, K., Butler, L. M., Sakko, A., Ricciardelli, C., Mitto, T. B., Octnick, A., . . . Tilley, W. D. (2010). Androgen receptor levels during progression of prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Medical Journal of Indonesia, 19(1), 5-13. DOI Scopus2 WoS2
2009	Peters, A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M., Harris, J., . . . Tilley, W. (2009). Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Research, 69(15), 6131-6140. DOI Scopus328 WoS295 Europe PMC225
2009	Gardiner, R., Sweeney, C., & Tilley, W. (2009). Testosterone Therapy in Castrate-Resistant Prostate Cancer: A Possible New Approach. European Urology, 56(2), 245-246. DOI Scopus8 WoS7 Europe PMC6
2009	Need, E., Scher, H., Peters, A., Moore, N., Cheong, A., Ryan, C., . . . Buchanan, G. (2009). A Novel Androgen Receptor Amino Terminal Region Reveals Two Classes of Amino/Carboxyl Interaction-Deficient Variants with Divergent Capacity to Activate Responsive Sites in Chromatin. Endocrinology, 150(6), 2674-2682. DOI Scopus25 WoS24 Europe PMC21
2009	Ricciardelli, C., Sakko, A., Stahl, J., Tilley, W., Marshall, V., & Horsfall, D. (2009). Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome. Prostate, 69(7), 761-769. DOI Scopus18 WoS17 Europe PMC9
2009	Chiam, K., Tilley, W., Butler, L., & Bianco-Miotto, T. (2009). The dynamic and static modification of the epigenome by hormones: A role in the developmental origin of hormone related cancers. Biochimica et Biophysica Acta-Reviews on Cancer, 1795(2), 104-109. DOI Scopus16 WoS17 Europe PMC11
2009	Baglietto, L., English, D., Hopper, J., MacInnis, R., Morris, H., Tilley, W., . . . Giles, G. (2009). Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Research and Treatment, 115(1), 171-179. DOI Scopus106 WoS93 Europe PMC80
2009	Marrocco, D., Centenera, M., Scher, H., Tilley, W., & Butler, L. (2009). Finding the place of histone deacetylase inhibitors in prostate cancer therapy. Expert Review of Clinical Pharmacology, 2(6), 619-630. DOI Scopus5 Europe PMC4
2008	Centenera, M., Harris, J., Tilley, W., & Butler, L. (2008). The Contribution of Different Androgen Receptor Domains to Receptor Dimerization and Signaling. Molecular Endocrinology, 22(11), 2373-2382. DOI Scopus116 WoS103 Europe PMC79
2008	Sakko, A., Butler, M., Byers, S., Reinboth, B., Stahl, C., Kench, J., . . . Ricciardelli, C. (2008). Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. Cancer Epidemiology Biomarkers & Prevention, 17(9), 2488-2497. DOI Scopus26 WoS25 Europe PMC14
2008	Cops, E., Bianco-Miotto, T., Moore, N., Clarke, C., Birrell, S., Butler, L., & Tilley, W. (2008). Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. Journal of Steroid Biochemistry and Molecular Biology, 110(3-5), 236-243. DOI Scopus60 WoS58 Europe PMC44
2008	Ricciardelli, C., Jackson, M., Choong, C., Stahl, J., Marshall, V., Horsfall, D., & Tilley, W. (2008). Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate, 68(8), 830-838. DOI Scopus39 WoS36 Europe PMC33
2007	Reichardt, J., & Tilley, W. (2007). The 3rd Pacific Rim meeting on breast and prostate cancer: Progress in hormonal carcinogenesis and the enduring influence of Ron Ross. Cancer Research, 67(10), 4550-4552. DOI Scopus1
2007	Buchanan, G., Ricciardelli, C., Harris, J., Prescott, J., Yu, Z., Jia, L., . . . Tilley, W. (2007). Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine-rich tetratricopeptide repeat containing protein α. Cancer Research, 67(20), 10087-10096. DOI Scopus79 WoS76 Europe PMC64
2007	Jariwala, U., Prescott, J., Jia, L., Barski, A., Pregizer, S., Cogan, J., . . . Frenkel, B. (2007). Identification of novel androgen receptor target genes in prostate cancer. Molecular Cancer, 6(1), WWW 1-WWW 15. DOI Scopus82 WoS70 Europe PMC57
2007	Birrell, S., Butler, L., Harris, J., Buchanan, G., & Tilley, W. (2007). Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB Journal, 21(10), 2285-2293. DOI Scopus79 WoS67 Europe PMC54
2007	Robzyk, K., Oen, H., Buchanan, G., Butler, L., Tilley, W., Mandal, A., . . . Caplan, A. (2007). Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor. Molecular and Cellular Endocrinology, 268(1-2), 67-74. DOI Scopus8 WoS10 Europe PMC8
2007	Dwivedi, P., Anderson, P., Tilley, W., May, B., & Morris, H. (2007). Role of oncoprotein Growth Factor Independent-1 (GFI1) in repression of 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1): A comparative analysis in human prostate cancer and kidney cells. Journal of Steroid Biochemistry and Molecular Biology, 103(3-5 Sp Iss), 742-746. DOI Scopus8 WoS6 Europe PMC6
2007	Ricciardelli, C., Russell, D., Ween, M., Mayne, K., Suwiwat, S., Byers, S., . . . Horsfall, D. (2007). Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. Journal of Biological Chemistry, 282(14), 10814-10825. DOI Scopus129 WoS124 Europe PMC98
2007	Baglietto, L., English, D., Hopper, J., Morris, H., Tilley, W., & Giles, G. (2007). Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiology Biomarkers & Prevention, 16(4), 763-768. DOI Scopus89 WoS70 Europe PMC56
2007	Sakko, A., Ricciardelli, C., Mayne, K., Dours-Zimmermann, M., Zimmermann, D., Neufing, P., . . . Horsfall, D. (2007). Changes in steroid receptors and proteoglycan expression in the guinea pig prostate stroma during puberty and hormone manipulation. Prostate, 67(3), 288-300. DOI Scopus9 WoS9 Europe PMC6
2007	Marrocco, D., Tilley, W., Bianco-Miotto, T., Evdokiou, A., Scher, H., Rifkind, R., . . . Butler, L. (2007). Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Molecular Cancer Therapeutics, 6(1), 51-60. DOI Scopus94 WoS83 Europe PMC71
2007	Chmelar, R., Buchanan, G., Need, E., Tilley, W., & Greenberg, N. (2007). Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. International Journal of Cancer, 120(4), 719-733. DOI Scopus212 WoS185 Europe PMC146
2007	Hayes, V., Severi, G., Padilla, E., Morris, H., Tilley, W., Southey, M., . . . Giles, G. (2007). 5 α-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. International Journal of Cancer, 120(4), 776-780. DOI Scopus52 WoS44 Europe PMC35
2006	Zeng, G., Day, T., Hooker, A., Blyth, B., Bhat, M., Tilley, W., & Sykes, P. (2006). Non-linear chromosomal inversion response in prostate after low dose X-radiation exposure. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 602(1-2), 65-73. DOI Scopus41 WoS35 Europe PMC26
2006	Butler, L., Liapis, V., Bouralexis, S., Welldon, K., Hay, S., Thai, L., . . . Evdokiou, A. (2006). The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. International Journal of Cancer, 119(4), 944-954. DOI Scopus72 WoS64 Europe PMC48
2006	Severi, G., Hayes, V., Neufing, P., Padilla, E., Tilley, W., Eggleton, S., . . . Giles, G. (2006). Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. Cancer Epidemiology Biomarkers & Prevention, 15(6), 1142-1147. DOI Scopus26 WoS24 Europe PMC18
2006	Severi, G., Morris, H., MacInnis, R., English, D., Tilley, W., Hopper, J., . . . Giles, G. (2006). Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiology Biomarkers & Prevention, 15(6), 1137-1141. DOI Scopus56 WoS55 Europe PMC37
2006	Butler, L., Centenera, M., Neufing, P., Buchanan, G., Choong, C., Ricciardelli, C., . . . Tilley, W. (2006). Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. Molecular Endocrinology, 20(5), 1009-1024. DOI Scopus15 WoS14 Europe PMC11
2006	Severi, G., Morris, H., MacInnes, R., English, D., Tilley, W., Hopper, J., . . . Giles, G. (2006). Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiology Biomarkers & Prevention, 15(1), 86-91. DOI Scopus156 WoS144 Europe PMC107
2005	Buchanan, G., Birrell, S., Peters, A., Bianco-Miotto, T., Ramsay, K., Cops, E., . . . Tilley, W. (2005). Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Research, 65(18), 8487-8496. DOI Scopus62 WoS58 Europe PMC48
2005	Han, G., Buchanan, G., Ittmann, M., Harris, J., Yu, X., DeMayo, F., . . . Greenberg, N. (2005). Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proceedings of the National Academy of Sciences of the United States of America, 102(4), 1151-1156. DOI Scopus156 WoS143 Europe PMC110
2005	Makridakis, N., Buchanan, G., Tilley, W., & Reichardt, J. (2005). Androgen metabolic genes in prostate cancer predisposition and progression. Frontiers in Bioscience, 10(SUPPL. 3), 2892-2903. DOI Scopus6 WoS5 Europe PMC4
2005	Shen, H., Buchanan, G., Butler, L., Prescott, J., Henderson, M., Tilley, W., & Coetzee, G. (2005). GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor.. Journal of Biological Chemistry, 386(1), 69-74. DOI Scopus25 WoS25 Europe PMC17
2004	Ricciardelli, C., Choong, C., Buchanan, G., Vivekanandan, S., Neufing, P., Stahl, J., . . . Tilley, W. (2004). Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate, 63(1), 19-28. DOI Scopus102 WoS94 Europe PMC73
2004	Jia, L., Choong, C., Ricciardelli, C., Kim, J., Tilley, W., & Coetzee, G. (2004). Androgen receptor signaling: mechanism of interleukin-6 inhibition. Cancer Research, 64(7), 2619-2626. DOI Scopus76 WoS66 Europe PMC46
2004	Buchanan, G., Yang, M., Cheong, A., Harris, J., Irvine, R., Lambert, P., . . . Tilley, W. (2004). Structural and functional consequences of glutamine tract variation in the androgen receptor. Human Molecular Genetics, 13(16), 1677-1692. DOI Scopus169 WoS161 Europe PMC120
2004	Scher, H., Buchanan, G., Gerald, W., Butler, L., & Tilley, W. (2004). Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocrine-Related Cancer, 11(3), 459-476. DOI Scopus209 WoS201 Europe PMC148
2004	Buchanan, G., Craft, C., Yang, M., Cheong, A., Prescott, J., Jia, L., . . . Tilley, W. (2004). PC-3 cells with enhanced androgen receptor signaling: A model for clonal selection in prostate cancer. Prostate, 60(4), 352-366. DOI Scopus31 WoS30 Europe PMC25
2004	Hooker, A., Morley, A., Tilley, W., & Sykes, P. (2004). Cancer-associated genes can affect somatic intrachromosomal recombination early in carcinogenesis. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 550(1-2), 1-10. DOI Scopus11 WoS9 Europe PMC8
2004	Hollington, P., Neufing, P., Kallionis, B., Waring, P., Bentel, J., Wattchow, D., & Tilley, W. (2004). Expression and localization of homeodomain proteins DLX4, HB9 and HB24 in malignant and benign human colorectal tissues. Anticancer Research, 24(2B), 955-962. Scopus24 WoS23 Europe PMC20
2004	Suwiwat, S., Ricciardelli, C., Tammi, R., Tammi, M., Auvinen, P., Kosma, V., . . . Horsfall, D. (2004). Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clinical Cancer Research, 10(7), 2491-2498. DOI Scopus134 WoS125 Europe PMC98
2004	Hall, R., Horsfall, D., Stahl, J., Vivekanandan, S., Ricciardelli, C., Stapleton, A., . . . Tilley, W. (2004). Apolipoprotein-D: A novel cellular marker for HGPIN and prostate cancer. Prostate, 58(2), 103-108. DOI Scopus29 WoS30 Europe PMC25
2003	Zhang, L., Brereton, H., Hahn, M., Froscio, M., Tilley, W., Brown, M., & Barritt, G. (2003). Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival. Cancer Gene Therapy, 10(8), 611-625. DOI Scopus9 WoS7 Europe PMC6
2003	Severi, G., Giles, G., Southey, M., Tesoriero, A., Tilley, W., Neufing, P., . . . Hopper, J. (2003). ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. Journal of the National Cancer Institute, 95(11), 818-824. DOI Scopus49 WoS45 Europe PMC33
2003	Kim, J., Jia, L., Tilley, W., & Coetzee, G. (2003). Dynamic methylation of histone H3 at lysine 4 in transcriptional regulation by the androgen receptor. Nucleic Acids Research, 31(23), 6741-6747. DOI Scopus36 WoS36 Europe PMC25
2003	Neufing, P., Kalionis, B., Horsfall, D., Ricciardelli, C., Stahl, J., Vivekanandan, S., . . . Tilley, W. (2003). Expression and localization of homeodomain proteins DLX4/HB9 in normal and malignant human breast tissues. Anticancer Research, 23(2B), 1479-1488. Scopus20 WoS19 Europe PMC17
2003	Sakko, A., Ricciardelli, C., Mayne, K., Suwiwat, S., LeBaron, R., Marshall, V., . . . Horsfall, D. (2003). Modulation of prostate cancer cell attachment to matrix by Versican. Cancer Research, 63(16), 4786-4791. Scopus77 WoS71 Europe PMC61
2003	Jia, L., Kim, J., Shen, H., Clark, P., Tilley, W., & Coetzee, G. (2003). Androgen receptor activity at the prostate specific antigen locus: Steroidal and non-steroidal mechanisms. Molecular Cancer Research, 1(5), 385-392. Scopus61 WoS59 Europe PMC41
2002	James, A., Agoulnik, I., Harris, J., Buchanan, G., Tilley, W., Marcelli, M., . . . Weigel, N. (2002). A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Molecular Endocrinology, 16(12), 2692-2705. DOI Scopus19 WoS16 Europe PMC12
2002	Buchanan, G., Irvine, R., Coetzee, G., & Tilley, W. (2002). Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer and Metastasis Reviews, 20(3-4), 207-223. DOI Scopus145 WoS135 Europe PMC96
2002	Jackson, M., Roberts, J., Heckford, S., Ricciardelli, C., Stahl, J., Horsfall, D., & Tilley, W. (2002). A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Research, 62(3), 854-859. Scopus172 WoS159 Europe PMC102
2001	Han, G., Foster, B., Mistry, S., Buchanan, G., Harris, J., Tilley, W., & Greenberg, N. (2001). Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. Journal of Biological Chemistry, 276(14), 11204-11213. DOI Scopus108 WoS105 Europe PMC73
2001	Buchanan, G., Yang, M., Harris, J., Nahm, H., Han, G., Moore, N., . . . Tilley, W. (2001). Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Molecular Endocrinology, 15(1), 45-56. DOI Scopus104 WoS96 Europe PMC62
2001	Sakko, A., Ricciardelli, C., Mayne, K., Tilley, W., LeBaron, R., & Horsfall, D. (2001). Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Research, 61(3), 926-930. Scopus94 WoS89 Europe PMC65
2001	Buchanan, G., Greenberg, N., Scher, H., Harris, J., Marshall, V., & Tilley, W. (2001). Collocation of androgen receptor gene mutations in prostate cancer. Clinical Cancer Research, 7(5), 1273-1281. Scopus171 WoS153 Europe PMC99
2001	Tilley, W. D., Clarke, C. L., Birrell, S. N., & Bruchovsky, N. (2001). Hormones and cancer: new insights, new challenges. Trends in endocrinology and metabolism: TEM, 12(5), 186-188. DOI Scopus3 Europe PMC3
2000	Park, J., Irvine, R., Buchanan, G., Koh, S., Park, J., Tilley, W., . . . Coetzee, G. (2000). Breast cancer susceptibility gene 1 (BRCA1) is a coactivator of the androgen receptor. Cancer Research, 60(21), 5946-5949. Scopus157 WoS134 Europe PMC96
1999	Bentel, J. M., Birrell, S. N., Pickering, M. A., Holds, D. J., Horsfall, D. J., & Tilley, W. D. (1999). Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Molecular and Cellular Endocrinology, 154(1-2), 11-20. DOI Scopus102 WoS97 Europe PMC75
1999	Bentel, J. M., Pickering, M. A., Pollard, M., Clements, J. A., & Tilley, W. D. (1999). Androgen receptor expression in primary prostate cancers of Lobund- Wistar rats and in tumor-derived cell lines. In Vitro Cellular and Developmental Biology - Animal, 35(10), 655-662. DOI Scopus7 WoS6 Europe PMC3
1999	Clements, J. A., Rohde, P., Allen, V., Hyland, V. J., Samaratunga, M. L. T. H., Tilley, W. D., . . . Gardiner, R. A. (1999). Molecular detection of prostate cells in ejaculate and urethral washings in men with suspected prostate cancer. Journal of Urology, 161(4), 1337-1343. DOI Scopus28 WoS25 Europe PMC12
1999	Ricciardelli, C., Quinn, D., Raymond, W., McCaul, K., Sutherland, P., Stricker, P., . . . Horsfall, D. (1999). Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Research, 59(10), 2324-2328. Scopus53 WoS52 Europe PMC35
1998	Birrell, S. N., Hall, R. E., & Tilley, W. D. (1998). Role of the Androgen Receptor in Human Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 3(1), 95-103. DOI Scopus114 WoS105 Europe PMC84
1998	Hall, R. E., Clements, J. A., Birrell, S. N., & Tilley, W. D. (1998). Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. British Journal of Cancer, 78(3), 360-365. DOI Scopus52 WoS46 Europe PMC31
1998	Zhang, S. X. D., Bentel, J. M., Ricciardelli, C., Horsfall, D. J., Haagensen, D. E., Marshall, V. R., & Tilley, W. D. (1998). Immunolocalization of apolipoprotein d, androgen receptor and prostate specific antigen in early stage prostate cancers. Journal of Urology, 159(2), 548-554. DOI Scopus21 WoS21 Europe PMC17
1997	Ricciardelli, C., Mayne, K., Sykes, P. J., Raymond, W. A., McCaul, K., Marshall, V. R., . . . Horsfall, D. J. (1997). Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clinical Cancer Research, 3(6), 983-992. Scopus82 WoS80 Europe PMC53
1997	Jackson, M. W., Bentel, J. M., & Tilley, W. D. (1997). Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. Journal of Urology, 157(6), 2323-2328. DOI Scopus178 WoS144 Europe PMC106
1996	Tilley, W. D., Buchanan, G., Hickey, T. E., & Bentel, J. M. (1996). Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clinical Cancer Research, 2(2), 277-285. Scopus347 WoS321 Europe PMC203
1996	Hall, R. E., Aspinall, J. O., Horsfall, D. J., Birrell, S. N., Bentel, J. M., Sutherland, R. L., & Tilley, W. D. (1996). Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer. British Journal of Cancer, 74(8), 1175-1180. DOI Scopus69 WoS69 Europe PMC47
1996	Choong, C. S., Sturm, M. J., Strophair, J. A., Mcculloch, R. K., Tilley, W. D., Leedman, P. J., & Hurley, D. M. (1996). Partial Androgen Insensitivity Caused by an Androgen Receptor Mutation at Amino Acid 907 (Gly→Arg) That Results in Decreased Ligand Binding Affinity and Reduced Androgen Receptor Messenger Ribonucleic Acid Levels. Journal of Clinical Endocrinology and Metabolism, 81(1), 236-243. DOI Scopus17 WoS15 Europe PMC8
1996	Bentel, J. M., & Tilley, W. D. (1996). Androgen receptors in prostate cancer. Journal of Endocrinology, 151(1), 1-11. DOI Scopus86 WoS83 Europe PMC43
1995	Greenberg, N. M., Demayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., . . . Rosen, J. M. (1995). Prostate cancer in a transgenic mouse. Proceedings of the National Academy of Sciences of the United States of America, 92(8), 3439-3443. DOI Scopus1112 WoS1052 Europe PMC760
1995	Birrell, S. N., Bentel, J. M., Hickey, T. E., Ricciardelli, C., Weger, M. A., Horsfall, D. J., & Tilley, W. D. (1995). Androgens induce divergent proliferative responses in human breast cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology, 52(5), 459-467. DOI Scopus227 WoS247 Europe PMC162
1995	Birrell, S. N., Roder, D. M., Horsfall, D. J., Bentel, J. M., & Tilley, W. D. (1995). Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. Journal of Clinical Oncology, 13(7), 1572-1577. DOI Scopus81 WoS75 Europe PMC54
1995	van Wezel, I. L., Umapathysivam, K., Tilley, W. D., & Rodgers, R. J. (1995). Immunohistochemical localization of basic fibroblast growth factor in bovine ovarian follicles. Molecular and Cellular Endocrinology, 115(2), 133-140. DOI Scopus74 WoS79 Europe PMC51
1995	Aspinall, J. O., Bentel, J. M., Horsfall, D. J., Haagensen, D. E., Marshall, V. R., & Tilley, W. D. (1995). Differential Expression of Apolipoprotein-D and Prostate Specific Antigen in Benign and Malignant Prostate Tissues. The Journal of Urology, 154(2), 622-628. DOI Scopus36 WoS35 Europe PMC20
1995	Tilley, W. D., Bentel, J. M., Aspinall, J. O., Hall, R. E., & Horsfall, D. J. (1995). Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3. Steroids, 60(1), 180-186. DOI Scopus44 WoS42 Europe PMC35
1994	Horsfall, D. J., Mayne, K., Ricciardelli, C., Mohan, R., Skinner, J. M., Henderson, D. W., . . . Tilley, W. D. (1994). Age-related changes in guinea pig prostatic stroma. Laboratory Investigation, 70(5), 753-763. DOI Scopus53 WoS46 Europe PMC36
1994	Ricciardelli, C., Horsfall, D. J., Sykes, P. J., Marshall, V. R., & Tilley, W. D. (1994). Effects of oestradiol 17-β and 5α-dihydrotestosterone on guinea-pig prostate smooth muscle cell proliferation and steroid receptor expression. Journal of Endocrinology, 140(3), 373-383. DOI Scopus21 WoS19 Europe PMC11
1994	Horsfall, D. J., Mayne, K., Skinner, J. M., Saccone, G. T. P., Marshall, V. R., & Tilley, W. D. (1994). Glycosaminoglycans of guinea pig prostate fibromuscular stroma: influence of estrogen and androgen on levels and location of chondroitin sulfate. The Prostate, 25(6), 320-332. DOI Scopus15 WoS16 Europe PMC11
1994	Tilley, W., Lim-Tio, S., Horsfall, D., Aspinall, J., Marshall, V., & Skinner, J. (1994). Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Research, 54(15), 4096-4102. Scopus118 WoS113 Europe PMC73
1994	Hall, R. E., Birrell, S. N., Tilley, W. D., & Sutherland, R. L. (1994). MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. European Journal of Cancer, 30A(4), 484-490. DOI Scopus91 WoS85 Europe PMC56
1992	Hall, R. E., Tilley, W. D., McPhaul, M. J., & Sutherland, R. L. (1992). Regulation of androgen receptor gene expression by steroids and retinoic acid in human breast‐cancer cells. International Journal of Cancer, 52(5), 778-784. DOI Scopus43 WoS47 Europe PMC27
1992	Marcelli, M., Tilley, W. D., Zoppi, S., Griffin, J. E., Wilson, J. D., & McPhaul, M. J. (1992). Molecular basis of androgen resistance. Journal of Endocrinological Investigation: Official Journal of the Italian Scociety of Endocrinology, 15(2), 149-159. DOI Scopus13 WoS17 Europe PMC9
1991	Marcelli, M., Tilley, W. D., Zoppi, S., Griffin, J. E., Wilson, J. D., & McPhaul, M. J. (1991). Androgen resistance associated with a mutation of the androgen receptor at amino acid 772 (Arg→Cys) results from a combination of decreased messenger ribonucleic acid levels and impairment of receptor function. Journal of Clinical Endocrinology and Metabolism, 73(2), 318-325. DOI Scopus66 WoS71 Europe PMC29
1991	McPhaul, M. J., Marcelli, M., Tilley, W. D., Griffin, J. E., & Wilson, J. D. (1991). Androgen resistance caused by mutations in the androgen receptor gene. FASEB Journal, 5(14), 2910-2915. DOI Scopus85 WoS79 Europe PMC37
1991	Gill, P. G., Tilley, W. D., De Young, N. J., Lensink, I. L., Dixon, P. D., & Horsfall, D. J. (1991). Inhibition of T47D human breast cancer cell growth by the synthetic progestin R5020: effects of serum, estradiol, insulin, and EGF. Breast Cancer Research and Treatment, 20(1), 53-62. DOI Scopus14 WoS15 Europe PMC8
1991	McPhaul, M. J., Marcelli, M., Tilley, W. D., Griffin, J. E., Isidro-Gutierrez, R. F., & Wilson, J. D. (1991). Molecular basis of androgen resistance in a family with a qualitative abnormality of the androgen receptor and responsive to high-dose androgen therapy. Journal of Clinical Investigation, 87(4), 1413-1421. DOI Scopus120 WoS123 Europe PMC67
1990	Marcelli, M., Tilley, W. D., Wilson, C. M., Wilson, J. D., Griffin, J. E., & McPhaul, M. J. (1990). A single nucleotide substitution introduces a premature termination codon into the androgen receptor gene of a patient with receptor-negative androgen resistance. Journal of Clinical Investigation, 85(5), 1522-1528. DOI Scopus79 WoS88 Europe PMC40
1990	Marcelli, M., Tilley, W. D., Wilson, C. M., Griffin, J. E., Wilson, J. D., & McPhaul, M. J. (1990). Definition of the human androgen receptor gene structure permits the identification of mutations that cause androgen resistance: Premature termination of the receptor protein at amino acid residue 588 causes complete androgen resistance. Molecular Endocrinology, 4(8), 1105-1116. DOI Scopus148 WoS151 Europe PMC67
1990	Tilley, W. D., Marcelli, M., & McPhaul, M. J. (1990). Expression of the human androgen receptor gene utilizes a common promoter in diverse human tissues and cell lines. Journal of Biological Chemistry, 265(23), 13776-13781. DOI Scopus106 WoS108 Europe PMC51
1990	Wilson, C. M., Tilley, W. D., Marcelli, M., & McPhaul, M. J. (1990). Androgen Receptor Gene Expression in Human Prostate Carcinoma Cell Lines. Cancer Research, 50(17), 5382-5386. Scopus225 WoS226 Europe PMC122
1990	Husmann, D. A., Wilson, C. M., Mcphaul, M. J., Tilley, W. D., & Wilson, J. D. (1990). Antipeptide antibodies to two distinct regions of the androgen receptor localize the receptor protein to the nuclei of target cells in the rat and human prostate. Endocrinology, 126(5), 2359-2368. DOI Scopus152 WoS163 Europe PMC79
1990	Tilley, W. D., Marcelli, M., & McPhaul, M. J. (1990). Recent studies of the androgen receptor: new insights into old questions. Molecular and Cellular Endocrinology, 68(2-3), C7-C10. DOI Scopus24 WoS24 Europe PMC12
1989	Tilley, W. D., Marcelli, M., Wilson, J. D., & McPhaul, M. J. (1989). Characterization and expression of a cDNA encoding the human androgen receptor. Proceedings of the National Academy of Sciences of the United States of America, 86(1), 327-331. DOI Scopus431 WoS439 Europe PMC188
1989	Tilley, W. D., Horsfall, D. J., Skinner, J. M., Henderson, D. W., & Marshall, V. R. (1989). Effect of pubertal development on estrogen receptor levels and stromal morphology in the guinea pig prostate. The Prostate, 15(2), 195-210. DOI Scopus17 WoS21 Europe PMC14
1989	Cooper, J. A., Rohan, T. E., Cant, E. L. M. K., Horsfall, D. J., & Tilley, W. D. (1989). Risk factors for breast cancer by oestrogen receptor status: A population-based case-control study. British Journal of Cancer, 59(1), 119-125. DOI Scopus116 WoS103 Europe PMC65
1989	Horsfall, D. J., Jarvis, L. R., Grimbaldeston, M. A., Tilley, W. D., & Orell, S. R. (1989). Immunocytochemical assay for oestrogen receptor in fine needle aspirates of breast cancer by video image analysis. British Journal of Cancer, 59(1), 129-134. DOI Scopus17 WoS19 Europe PMC13
1989	Horsfall, D. J., Goldsmith, K. G., Ricciardelli, C., Skinner, J. M., Tilley, W. D., & Marshall, V. R. (1989). Steroid hormone and epidermal growth factor receptors in meningiomas. Australian and New Zealand Journal of Surgery, 59(11), 881-888. DOI Scopus16 WoS16 Europe PMC12
1989	Ricciardelli, C., Horsfall, D. J., Skinner, J. M., Henderson, D. W., Marshall, V. R., & Tilley, W. D. (1989). Development and characterization of primary cultures of smooth muscle cells from the fibromuscular stroma of the guinea pig prostate. In Vitro Cellular & Developmental Biology, 25(11), 1016-1024. DOI Scopus29 WoS32 Europe PMC23
1987	Tilley, W. D., Horsfall, D. J., McGee, M. A., Alderman, J. E., & Marshall, V. R. (1987). Effects of ageing and hormonal manipulations on the level of oestrogen receptors in the guinea-pig prostate. Journal of Endocrinology, 112(1), 139-144. DOI Scopus11 WoS11 Europe PMC8
1987	van Haaften‐Day, C., Raghavan, D., Russell, P., Wills, E. J., Gregory, P., Tilley, W., & Horsfall, D. J. (1987). Xenografted small cell undifferentiated cancer of prostate: Possible common origin with prostatic adenocarcinoma. The Prostate, 11(3), 271-279. DOI Scopus57 WoS56 Europe PMC37
1986	Horsfall, D. J., Tilley, W. D., Orell, S. R., Marshall, V. R., & Cant, E. L. M. K. (1986). Relationship between ploidy and steroid hormone receptors in primary invasive breast cancer. British Journal of Cancer, 53(1), 23-28. DOI Scopus70 WoS82 Europe PMC51
1985	Tilley, W. D., Horsfall, D. J., McGee, M. A., Henderson, D. W., & Marshall, V. R. (1985). Distribution of oestrogen and androgen receptors between the stroma and epithelium of the guinea-pig prostate. Journal of Steroid Biochemistry, 22(6), 713-719. DOI Scopus25 WoS28 Europe PMC16
1985	Tilley, W. D., Horsfall, D. J., Cant, E. L. M. K., & Marshall, V. R. (1985). Specific binding of oestradiol to guinea-pig prostate cytosol and nuclear fractions. Journal of Steroid Biochemistry, 22(6), 705-711. DOI Scopus12 WoS12 Europe PMC5
1982	Tilley, W. D., & Marshall, V. R. (1982). Steroid hormone receptors in the guinea-pig prostate: Effect of castration. Clinical and Experimental Pharmacology and Physiology, 9(5), 527-528.
1981	Tilley, W., Keightley, D., & Marshall, V. (1981). Properties of the cytoplasmic and nuclear oestrogen receptor in the guinea-pig prostate. Clinical and Experimental Pharmacology and Physiology, 8(4).
1981	Tilley, W., Keightley, D., & Marshall, V. (1981). Oestrogen and androgen receptors in benign prostatic hyperplasia and carcinoma of the prostate. British Journal of Urology, 53(1), 74.
1980	Tilley, W. D., Keightley, D. D., & Marshall, V. R. (1980). Steroid hormone receptors in human benign prostatic hypertrophy (BPH). Clinical and Experimental Pharmacology and Physiology, 7(4), 442-443.
1980	Tilley, W. D., Keightley, D. D., & Marshall, V. R. (1980). Oestrogen and progesterone receptors in benign prostatic hyperplasia in humans. Journal of Steroid Biochemistry, 13(4), 395-399. DOI Scopus27 WoS28 Europe PMC19
1978	Tilley, W. D., Keightley, D. D., & Cant, E. L. M. (1978). Inter-site variation of oestrogen receptors in human breast cancers. British Journal of Cancer, 38(4), 544-546. DOI Scopus32 WoS43 Europe PMC26
1978	Keightley, D. D., Tilley, W. D., & Cant, E. L. M. (1978). Effect of snap freezing, dithiothreitol and storage on estimations of estrogen receptor sites. Clinica Chimica Acta, 88(2), 337-343. DOI Scopus8 WoS9 Europe PMC4

Book Chapters

Year	Citation
2014	Moore, N., Centenera, M., Butler, L., Hickey, T., & Tilley, W. (2014). Androgens and the androgen receptor (AR). In E. Gelmann, C. Sawyers, & F. Rauscher (Eds.), Molecular oncology: Causes of cancer and targets for treatment (1 ed., pp. 378-391). Cambridge, United Kingdom: Cambridge University Press. DOI
2013	Selth, L., Townley, S., Gillis, J., Tilley, W., & Butler, L. (2013). Identification of prostate cancer-associated microRNAs in circulation using a mouse model of disease. In T. Ochiya (Ed.), Circulating MicroRNAs. Methods and Protocols (Vol. 1024, pp. 235-246). UK: Springer. DOI Scopus3 Europe PMC3
2013	Selth, L. A., Townley, S. L., Gillis, J. L., Tilley, W. D., & Butler, L. M. (2013). Identification of Prostate Cancer-Associated MicroRNAs in Circulation Using a Mouse Model of Disease. In Methods in Molecular Biology (pp. 235-246). Humana Press. DOI
2009	Buchanan, G., Need, E., Bianco-Miotto, T., Greenberg, N., Scher, H., Centenera, M., . . . Tilley, W. (2009). Insights from AR gene mutations. In D. Tindall, & J. Mohler (Eds.), Androgen action in prostate cancer (pp. 207-240). Dordrecht, Netherlands: Springer. DOI Scopus4
2008	Beekman, K. W., Buchanan, G., Tilley, W. D., & Scher, H. I. (2008). Antiandrogen withdrawal syndromes: Pathophysiology and clinical implications. In Treatment Methods for Early and Advanced Prostate Cancer (pp. 317-325).
2006	Beekman, K., Buchanan, G., Tilley, W., & Scher, H. (2006). Antiandrogen withdrawal syndromes: pathophysiology and clinical implications. In R. S. Kirby, A. W. Partin, M. Feneley, & J. Kellogg Parsons (Eds.), Prostate cancer: principles and practice (pp. 979-988). London: Taylor & Francis.
2005	Beekman, K., Tilley, W., & Buchanan, G. (2005). Beyond first-line hormones: options for treatment of castration-resistant disease. In Comprehensive textbook of genitourinary oncology (pp. 330-340). Broadway, NSW: Lippincott Williams & Wilkins.
2003	Tilley, W., Buchanan, G., & Coetzee, G. (2003). Androgen receptor signaling in prostate cancer. In B. Henderson, B. Ponder, & R. Ross (Eds.), Hormones, genes, and cancer (pp. 288-315). 198 Madison Ave, New York, NY 10016: Oxford University Press.
-	Antiandrogen withdrawal syndromes: Pathophysiology and clinical implications (n.d.).

Conference Papers

Year	Citation
2020	Lim, E., Milioli, H. H., Alexandrou, S., Coulson, R., Yong, A., Fernandez, K. J., . . . Portman, N. (2020). MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 16 (pp. 110). WILEY.
2017	Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Butler, L. (2017). Lipid elongation: an unexplored therapeutic target in prostate cancer. In CANCER RESEARCH Vol. 77 (pp. 2 pages). Washington, DC: AMER ASSOC CANCER RESEARCH. DOI
2017	Shafi, A. A., Schiewer, M. J., de Leeuw, R., McCue, P. A., Gomella, L. G., Lallas, C. D., . . . Knudsen, K. E. (2017). PDeX (Patient Derived eXplant) models to determine the basis for response to targeted agents in prostate cancer. In CANCER RESEARCH Vol. 77 (pp. 2 pages). Washington, DC: AMER ASSOC CANCER RESEARCH. DOI
2013	Morel, K., Ormsby, R., Bezak, E., Tilley, W., Lawrence, M., & Sykes, P. (2013). Parthenolide as a selective radiosensitiser in the treatment and prevention of prostate cancer. In BJU International Vol. 112 (pp. 45). Melbourne: Wiley.
2012	Ochnik, A. M., Moore, N. L., Birrell, S. N., Butler, L. M., Jindal, S., Selth, L., . . . Hickey, T. E. (2012). The combined actions of DHT and MPA lead to altered AR signaling in normal and malignant post-menopausal breast epithelial cells. In Cancer Research Vol. 72 (pp. 2). Chicago, IL: American Association for Cancer Research. DOI
2009	Butler, L., Centenera, M., Marrocco, D., Carter, S., Bianco-Miotto, T., & Tilley, W. (2009). A novel combinatorial approach using androgen receptor-targeted agents for treatment of prostate cancer. In Cancer Research Vol. 69 (pp. 2 pages). American Association for Cancer Research.
2006	Murphy, N., Bianco-Miotto, T., Ricciardelli, C., Ruiz, A., Segara, D., McNeil, C., . . . Tilley, W. (2006). Expression of the androgen receptor and its association with disease outcome in breast cancer. In Breast Cancer Research and Treatment Vol. 100 (pp. S262-S263). San Antonio, Texas: Springer.
1987	MARSHALL, V. R., TILLEY, W. D., & HORSFALL, D. J. (1987). LOCALIZATION AND REGULATION OF THE PROSTATIC ESTROGEN-RECEPTOR. In BRITISH JOURNAL OF UROLOGY Vol. 59 (pp. 182). BLACKWELL SCIENCE LTD.
1981	TILLEY, W. D., KEIGHTLEY, D. D., & MARSHALL, V. R. (1981). ESTROGEN AND ANDROGEN RECEPTORS IN BENIGN PROSTATIC HYPERPLASIA AND CARCINOMA OF THE PROSTATE. In BRITISH JOURNAL OF UROLOGY Vol. 53 (pp. 74). BLACKWELL SCIENCE LTD.
1979	TILLEY, W. D., KEIGHTLEY, D. D., & MARSHALL, V. R. (1979). HORMONE RECEPTORS IN BENIGN PROSTATIC HYPERPLASIA. In AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY Vol. 49 (pp. 147). BLACKWELL SCIENCE.
1978	KEIGHTLEY, D. D., TILLEY, W. D., & CANT, E. L. M. (1978). STORAGE OF TISSUE TO BE USED IN ESTROGEN-RECEPTOR ASSAYS. In AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY Vol. 48 (pp. 224). BLACKWELL SCIENCE.

Conference Items

Year	Citation
2021	Portman, N., Milioli, H., Alexandrou, S., Coulson, R., Yong, A., Fernandez, K., . . . Lim, E. (2021). Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
2021	Lau, B., Segara, D., Ong, A., Bingham, J., Kiely, B., Carson, E. -K., . . . Lim, E. (2021). Winpro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
2020	Butler, L. M., Mah, C. Y., Dehairs, J., Vincent, A., Mutuku, S., Spotbeen, X., . . . Swinnen, J. (2020). Phospholipid profiling of clinical prostate tissues reveals targetable alterations in membrane lipid composition accompanying tumorigenesis. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH. DOI
2020	Lim, E., Hickey, T. A., Selth, L. A., Chia, K. M., Milioli, H. H., Roden, D., . . . Tilley, W. D. (2020). The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer. Poster session presented at the meeting of CANCER RESEARCH. San Antonio, TX: AMER ASSOC CANCER RESEARCH. DOI
2020	Shrestha, R. K., Townley, S., Hanson, A., Pickering, M., Nassar, Z. D., Mah, C. Y., . . . Selth, L. A. (2020). ACSM1 and ACSM3 regulate fatty acid oxidation in prostate cancer to promote growth and protect against oxidative stress.. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH. WoS1
2019	Shafi, A. A., Schiewer, M. J., de Leeuw, R., Dylgjeri, E., Mccue, P. A., Shah, N., . . . Knudsen, K. E. (2019). Patient derived models reveal impact of the tumor microenvironment on therapeutic response. Poster session presented at the meeting of CANCER RESEARCH. Atlanta, GA: AMER ASSOC CANCER RESEARCH. DOI
2019	Winter, J. M., Mustafa, E. H., Wang, S., Selth, L. A., Hickey, T. E., & Tilley, W. D. (2019). Novel and highly selective CDK9 inhibitors suppress proliferation of triple negative breast cancer (TNBC) cells <i>in vitro</i>. Poster session presented at the meeting of CANCER RESEARCH. Atlanta, GA: AMER ASSOC CANCER RESEARCH. DOI WoS1
2018	Daniel, M. L., Hickey, T. E., Carroll, J. S., Tilley, W. D., Selth, L. A., & Dehm, S. M. (2018). Deciphering the regulome of androgen receptor variants in prostate cancer. Poster session presented at the meeting of CANCER RESEARCH. Chicago, IL: AMER ASSOC CANCER RESEARCH. DOI
2018	Zhang, A. Y., Chiam, K., Haupt, Y., Fox, S. B., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy. Poster session presented at the meeting of Journal of Clinical Oncology. San Francisco, CA: American Society of Clinical Oncology. DOI
2018	Zhang, A., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis after radical prostatectomy. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. Adelaide: Wiley.
2018	Nassar, Z. D., Centenera, M. M., Machiels, J., Zinonos, I., Hanson, A., Bloch, K., . . . Swinnen, J. V. (2018). Lipid elongation in prostate cancer is androgen regulated and a potential therapeutic target. Poster session presented at the meeting of BJU International. Brisbane, Australia: Wiley.
2018	Zhang, A., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis after radical prostatectomy. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. Sydney: Wiley.
2017	Tilley, W. (2017). Steroid receptor cross talk in breast cancer: molecular insights and therapeutic implications. Poster session presented at the meeting of Clinical Endocrinology. Broadbeach, Queensland: Wiley.
2017	Tilley, W. (2017). Steroid receptor RIMEs in breast and prostate cancer. Poster session presented at the meeting of Clinical Endocrinology. Broadbeach, Queensland: Wiley.
2016	Tilley, W. (2016). Targeting progesterone and androgen receptors to enhance er-target therapies in breast cancer. Poster session presented at the meeting of Asia-Pacific Journal of Clnical Oncology. Wiley.
2016	Tarulli, G. A., Laven-Law, G., Tilley, W. D., & Hickey, T. E. (2016). Unraveling an identity for the androgen receptor-expressing mammary epithelial cell. Poster session presented at the meeting of Clinical Endocrinology. Adelaide: Wiley.
2016	Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Swinnen, J. V. (2016). Androgenic regulation of lipid elongation in prostate cancer. Poster session presented at the meeting of BJU International. Melbourne: Wiley.
2016	Asim, M., Massie, C., Warren, A., Luko, K., Chohan, B., Menon, S., . . . Neal, D. (2016). Androgen-regulated proteome reveals a therapeutically relevant androgen receptor coactivator target in prostate cancer. Poster session presented at the meeting of CANCER RESEARCH. New Orleans, LA: AMER ASSOC CANCER RESEARCH. DOI
2014	Zhuang., Rodriguez Lopez., Chiam, K., Harryanto, H., Ryan, N., Jindal, S., . . . Bianco-Miotto. (2014). A high fat diet early in life and prostate cancer risk. Poster session presented at the meeting of The Australian Health and Medical Research Congress. Melbourne, Australia.
2014	Zhang, A. Y., Butler, L. M., Stricker, P. D., Kench, J. G., Tilley, W. D., Sebastian, L., . . . Horvath, L. (2014). Pharmacodynamic effects of the heat shock protein 90 (HSP90) inhibitor, AUY922, in high-risk, localised prostate cancer. Poster session presented at the meeting of Asia-Pacific Journal Of Clinical Oncology. Melbourne, Vic.: Wiley. DOI WoS1
2014	Roberts, M., Selth, L., Chow, C., Doi, S., Vincent, A., Butler, L., . . . Gardiner, R. (2014). Seminal fluid microRNAs: new, non-invasive biomarkers for prostate cancer. Poster session presented at the meeting of BJU International. Brisbane: Wiley.
2014	Ravindranathan, P., Tilley, W., & Raj, G. V. (2014). Rational targeting of the Androgen receptor interactome in prostate cancer. Poster session presented at the meeting of Cancer Research. San Diego, CA: American Association for Cancer Research. DOI
2014	Oh, T. G., Bailey, P., Dray, E., Goode, J., Eriksson, N., Funder, J. W., . . . Muscat, G. E. (2014). Breast cancer and metastasis free survival are effected by PRMT2 and Rory; Expression: Understanding the Role of DNA Repair. Poster session presented at the meeting of Endocrine Reviews. Chicago: Endocrine Society.
2014	Hickey, T. E., Robinson, J. L., Moore, N. L., Russell, R., Selth, L., Rueda, O., . . . Tilley, W. D. (2014). The androgen receptor restricts estrogen receptor Alpha DNA binding in breast cancer cells. Poster session presented at the meeting of Endocrine Reviews. Chicago: Endocrine Society.
2014	Philp, L. K., Day, T. K., Butler, M. S., Jindal, S., Butler, L. M., & Tilley, W. D. (2014). Full, but Not Partial, Sgta Ablation Confers Subfertility and Limits Offspring Viability and Growth in Mice. Poster session presented at the meeting of ENDOCRINE REVIEWS. ENDOCRINE SOC.
2013	Tilley, W. (2013). Androgens: role in aging & prostate cancer - non castrate and castrate resistant states. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. Adelaide: Wiley.
2013	Tilley, W., & Hickey, T. (2013). Androgen-receptor: A two-edge sword?. Poster session presented at the meeting of European Journal of Cancer. Amsterdam, Netherlands: Elsevier.
2013	Philp, L., Day, T., Jindal, S., Pickering, M., Butler, L., & Tilley, W. (2013). Protein expression alterations in a unique gleason prostate cancer progression cohort. Poster session presented at the meeting of BJU International. Melbourne: Wiley.
2013	Sykes, P., Ormsby, R., Blyth, B., Bezak, E., Newman, M., Tilley, W., & Lawrence, M. (2013). Lack of a low-dose radiation adaptive response on prostate cancer progression in the TRAMP model. Poster session presented at the meeting of BJU International. Melbourne: Wiley.
2013	Proctor, L. A., Hanson, A. R., Butler, M. S., Tilley, W. D., & Moore, N. L. (2013). Cyclin-dependent kinase 2 regulates androgen receptor activity in estrogen receptor negative breast cancer. Poster session presented at the meeting of Molecular Cancer Research. San Diego, CA: American Association for Cancer Research. DOI
2011	Bianco-Miotto, T., Chiam, K., Jindal, S., Ryan, N., Zulkifli, S., Moretta, S., . . . Owens, J. (2011). Early life exposure to a high fat diet results in histological and molecular changes in the rat prostate which are transmitted paternally to the second generation. Poster session presented at the meeting of Journal of Developmental Origins of Health and Disease. Portland, Oregon: Cambridge University Press.
2010	Centenera, M. M., Treloar, J. L., Hanson, A., Sutherland, P., Tilley, W. D., & Butler, L. M. (2010). Evaluation of the synthetic heat shock protein 90 inhibitors NVP-AUY922 and NVP-HSP990 in human prostate cancer tissue. Poster session presented at the meeting of European Journal of Cancer Supplements. Berlin, Germany: Elsevier. DOI
2009	Birrell, S. N., & Tilley, W. D. (2009). Testosterone undecanoate treatment reduces joint morbidities induced by anastrozole therapy in postmenopausal women with breast cancer: results of a double-blind, randomized phase ii trial. Poster session presented at the meeting of Cancer Research. San Antonio, Texas: American Association for Cancer Research. DOI WoS3
2009	Jankovic-Karasoulos, T., Birrell, S. N., Cops, E. J., Jindal, S., Ochnik, A., Thomas, M., . . . Hickey, T. E. (2009). Evaluation of testosterone supplementation during anastrozole therapy in a breast explant model. Poster session presented at the meeting of Cancer Research. San Antonio, Texas: American Association for Cancer Research. DOI
2008	Hickey, T., Butler, M., Ricciardelli, C., Norman, R., & Tilley, W. (2008). Expression of small glutamine-rich tetratricopeptide repeat-containing protein alpha (alpha SGT), a novel regulator of androgen receptor (AR) activity, in the human ovary and fallopian tube. Poster session presented at the meeting of Biology of Reproduction. Kailua-Kona, Hawaii: Oxford University Press. DOI WoS1
2008	Hickey, T., Ocknik, A., Bianco-Miotto, T., Birrell, S., Butler, L., & Tilley, W. (2008). Functional androgen signaling in an explant model of normal human breast tissue. Poster session presented at the meeting of Biology of Reproduction. Kailua-Kona, Hawaii: Oxford University Press. DOI
2006	Buchanan, G., Ricciardelli, C., Prescott, J., Harris, J. M., Yu, Z. C. -L., Jia, L., . . . Tilley, W. D. (2006). αSGT: A critical determinant of androgen receptor function in prostate cancer. Poster session presented at the meeting of Cancer Research. Washington, DC: American Association for Cancer Research.

NHMRC Ideas Grant

APP1186647

2020-2023

$1,148,310

A combinatorial drug strategy to target lethal forms of breast cancer.

W.D. Tilley, E. Lim, R. Iggo, J. Carroll

NHMRC Project Grant

APP1145777

2018-2021

$998,754

Pushing AR toward better outcomes in breast and prostate cancers.

W.D. Tilley, T. Hickey, L. Selth, J. Carroll, E. Lim, W. Zwart, A. Joshua, C. Sweeney

NHMRC Project Grant APP1138242

2018-2021

$799,440

A novel strategy for targeting castrate-resistant prostate cancer.

G. Risbridger, W.D. Tilley, L. Furic, S. Sandhu, A. Azad, L. Selth, M. Lawrence

Movember and National Breast Cancer Foundation, Australia

2018-2021

$2,958,714

Transforming endocrine therapy for breast and prostate cancer.

W.D. Tilley, G. Risbridger, J. Carroll, E. Lim, S. Clark, T. Hickey, L. Selth

The Hospital Research Foundation, Australia

2018-2021

$375,000.00

Transforming therapy for breast and prostate cancer.

W.D. Tilley, T. Hickey, L. Selth

NHMRC Development Grant

APP1135682

2018-2020

$1,171,199

Development of a novel and highly selective CDK4/6 inhibitor for treating cancer.

S. Wang, R. Milne, W.D. Tilley, E. Lim

Cancer Research UK, Cambridge University

A23654

2018-2020

£193,783

PEARL Study: A window of opportunity study to assess the biological effects of progesterone in premenopausal ER-positive, PgR-positive early breast cancer.

C. Palmieri, W.D. Tilley, S. Chauhan, C. Rawcliffe, J. Neoptolemos, J. Carroll, E. Lim

NHMRC Project Grant APP1121057

2017-2020

$959,423

Dual targeting of the Androgen Receptor for Effective and Durable Control of Lethal Prostate Cancer.

W.D. Tilley, G. Risbridger, G. Raj, L. Selth, J. Taylor, A. Joshua

NHMRC Project Grant

APP1130077

2017-2020

$1,023,132

The clinical significance of sex hormone receptor crosstalk in ER+ breast cancer.

W.D. Tilley, J. Carroll, T. Hickey, E. Lim, L. Selth, E. Ebrahimie, S. Birrell, C. Palmieri, G. Greene, A. Bruna, C. Lange, F. Classens, N. Dean, F. Markowetz, A. Swarbrick

Cancer Council of NSW

2017-2019

$450,000

WinPro: Progesterone as an anticancer therapy in early breast cancer.

E. Lim, W.D. Tilley

Current Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2024	Co-Supervisor	Selective Androgen Receptor Modulators (SARMs) for the Treatment of Androgen Receptor positive (AR+) and Estrogen Receptor Positive (ER+) Breast Cancer.	Doctor of Philosophy	Doctorate	Full Time	Mr Manjit Rana
2023	Co-Supervisor	Role of Androgen Receptor Signalling in the Metastasis of Estrogen Receptor Positive Breast Cancer	Doctor of Philosophy	Doctorate	Full Time	Ms Dana Basem Mohamad Al Safadi
2023	Principal Supervisor	Investigating the role of androgen receptors in bladder cancer	Doctor of Philosophy	Doctorate	Full Time	Mr Ahmed Faris Abdulridha Aldoghachi
2022	Co-Supervisor	An Innovative Treatment Strategy for Hormone-Dependent Cancers	Doctor of Philosophy	Doctorate	Full Time	Ms Maliha Wajahat .
2021	Principal Supervisor	Exploring the Role of Steroid Receptors in ER+ Breast Cancer	Doctor of Philosophy	Doctorate	Full Time	Mr Alex Adrian Pace

Past Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2021 - 2023	Co-Supervisor	Unlocking Insights from Complex Transcriptomic Data: Novel Bioinformatics Methods for Neurodegeneration and Cancer Studies	Doctor of Philosophy	Doctorate	Full Time	Miss Nora Liu
2019 - 2023	Co-Supervisor	Investigating USP2 as a mediator of therapy resistance in lethal prostate cancer	Doctor of Philosophy	Doctorate	Full Time	Ms Meiwen Danielle Fang
2017 - 2021	Co-Supervisor	Role of the GATA3 Transcription Factor on AR Signalling in Breast Cancer	Doctor of Philosophy	Doctorate	Full Time	Mrs Leila Hosseinzadeh
2017 - 2021	Co-Supervisor	Elucidating the molecular mechanisms underlying androgen-regulated lipid metabolism in prostate cancer	Doctor of Philosophy	Doctorate	Full Time	Mr Raj Kumar Shrestha
2017 - 2021	Co-Supervisor	Development of a Novel Therapeutic Strategy for Estrogen Receptor Negative Breast Cancer	Doctor of Philosophy	Doctorate	Full Time	Mrs Ebtihal Hashem Mustafa
2017 - 2021	Co-Supervisor	Extreme Activation of Androgen Receptor for Prostate Cancer Therapy	Doctor of Philosophy	Doctorate	Full Time	Mr Mohammadreza Alizadeh Ghodsi
2016 - 2020	Co-Supervisor	The Role of MicroRNA-194 in Prostate Cancer Progression	Doctor of Philosophy	Doctorate	Full Time	Miss Rayzel Candida Fernandes
2010 - 2016	Co-Supervisor	The Role of Estrogen Receptor and the Androgen Receptor in Human Breast Cancer	Doctor of Philosophy	Doctorate	Part Time	Mrs Shalini Jindal
2009 - 2013	Co-Supervisor	Investigation into the Expression and Localisation of C-Kit and the Regulation of Kit Ligand Gene Expression in the Adult Human Ovary	Doctor of Philosophy	Doctorate	Full Time	Dr Astrud Tuck
2008 - 2012	Co-Supervisor	The Molecular Actions of Medroxyprogesterone Acetate on Androgen Receptor Signalling and the Promotion of Breast Cancer	Doctor of Philosophy	Doctorate	Full Time	Miss Aleksandra Ochnik
2008 - 2011	Co-Supervisor	Characterisation of the Co-chaperone Small Glutamine-rich Tetratricopeptide Repeat containing Protein Alpha as a Regulator of Androgen Receptor Activity in Prostate Cancer Cells	Doctor of Philosophy	Doctorate	Full Time	Dr Andrew Trotta
2008 - 2012	Co-Supervisor	The Role of Small Glutamine-Rich Tetratricopeptide Repeat Containing Protein Alpha in Female Reproductive Tissues	Doctor of Philosophy	Doctorate	Full Time	Ms Miriam Simone Butler
2007 - 2012	Co-Supervisor	Mathematical Models of Cell Cycle Progression: Applications to Breast Cancer Cell Lines	Doctor of Philosophy	Doctorate	Part Time	Miss Kate Simms
2007 - 2015	Co-Supervisor	Combinatorial Targeting of the Androgen Receptor for Prostate Cancer Therapy	Doctor of Philosophy	Doctorate	Full Time	Miss Sarah Carter
2006 - 2010	Co-Supervisor	The Role of Epigenetic Modifications in Prostate Tumourigenesis	Doctor of Philosophy	Doctorate	Full Time	Ms Karen Huiqin Chiam
2004 - 2008	Co-Supervisor	Characterisation of a Dominant Negative Androgen Receptor in Prostate Cancer Cells	Doctor of Philosophy	Doctorate	Part Time	Dr Margaret Centenera
2004 - 2008	Co-Supervisor	Androgen Signalling in Normal and Malignant Breast Epithelial Cells	Doctor of Philosophy	Doctorate	Part Time	Ms Amelia Peters
2004 - 2008	Co-Supervisor	Androgens and Androgen Receptor Signalling in Men	Doctor of Philosophy	Doctorate	Full Time	Dr Eleanor Need
2003 - 2007	Principal Supervisor	Targeting the Androgen Receptor as a Therapeutic Strategy for Prostate Cancer	Doctor of Philosophy	Doctorate	Full Time	Miss Deborah Marrocco
2002 - 2004	Co-Supervisor	Versican: regulation, purification, and biological properties of a candidate prognostic indicator for breast cancer	Doctor of Philosophy	Doctorate	Full Time	Miss Supaporn Suwiwat
2002 - 2004	Principal Supervisor	ANDROGEN SIGNALLING IN HUMAN BREAST CANCER CELLS	Doctor of Philosophy	Doctorate	Full Time	Dr Nicole Moore

Other Supervision Activities

Date	Role	Research Topic	Location	Program	Supervision Type	Student Load	Student Name
2021 - ongoing	Principal Supervisor	Exploring the role of steroid receptors in ER+ breast cancer.	University of Adelaide	Doctor of Philosophy (Medical Science)	Doctorate	Full Time	Alex Pace

Industry Partnerships

Date Engagement Type Partner Name

2019 - ongoing Consultant Radius Health, Waltham, Massachusetts: Selective androgen receptor modulators (SARMs) and breast cancer program.
Review, Assessment, Editorial and Advice

Date Title Type Institution Country

2008 - ongoing Advisory Editor Journal Review Endocrine-Related Cancer -

2008 - ongoing Editorial Board Journal Review Oncology Times -

Date	Engagement Type	Partner Name
2019 - ongoing	Consultant	Radius Health, Waltham, Massachusetts: Selective androgen receptor modulators (SARMs) and breast cancer program.

Date	Title	Type	Institution	Country
2008 - ongoing	Advisory Editor	Journal Review	Endocrine-Related Cancer	-
2008 - ongoing	Editorial Board	Journal Review	Oncology Times	-

Position: Director - Dame Roma Mitchell Cancer Res Lab
Phone: 83137861
Email: wayne.tilley@adelaide.edu.au
Campus: North Terrace
Building: Adelaide Health and Medical Sciences, floor 8
Org Unit: Medical Specialties

Professor Wayne Tilley

Key Research Projects Available for DRMCRL

Appointments

Awards and Achievements

Education

Postgraduate Training

Research Interests

Journals

Book Chapters

Conference Papers

Conference Items

Current Higher Degree by Research Supervision (University of Adelaide)

Past Higher Degree by Research Supervision (University of Adelaide)

Other Supervision Activities

Industry Partnerships

Review, Assessment, Editorial and Advice

Connect With Me

External Profiles

Other Links